DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
i  
A Phase 1 Open Label, Multiple Ascending Dose Study of 
Oxfendazole in Healthy Adult Volunteers  
DMID Protocol Number:   16-0005  
 
DMID Funding Mechanism:   VTEU Contract Support  
Pharmaceutical Support Provided by:   [CONTACT_527856]:   Division of Microbiology and Infectious Diseases  
The National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
 
Principal Investigator:    [INVESTIGATOR_527843], MD  
DMID Medical Officer :  Greg ory Deye, MD  
DMID Medical Monitor: Soju Chang, MD  
DMID Clinical Project Manager : Effie Nomicos, RN , MSN, CCRP  
Version Number:   4.0 
24 July 2017  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
ii STATEMENT OF COMPLIA NCE  
This trial will be conducted in compliance with the protocol, International Conference on  
Harmonisation guideline E6:  Good Clinical Practice: Consolidated Guideline, the applicable 
regulatory requirements from US Code of Federal Regulations (CFR) (Title 45 CFR Part 46 and 
Title 21 CFR including Parts 50 and 56) concerning informe d consent and Institutional Review 
Board regulations, and the NIAID Clinical Terms of Award.  
All individuals respons ible for the design and conduct of this study have completed Human 
Subjects Protection Training and are qualified to be conduc ting this research prior to the 
enrollment of any subjects.  Curricula vitae for all investigators and subinvestigators participating 
in this trial are on file in a central facility (21 CFR 31 2.23 [a] [6] [iii] [b] edition). 
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
iii SIGNATURE [CONTACT_19841], and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local  legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Site Investigator: Patricia Winokur, MD  
 
Signed:   Date:   
 Name  
[CONTACT_527881] [ADDRESS_685257] of Abbreviations  vii 
Protocol Summary  ix 
1 Key Roles  1 
2 Background Information and Scientific Rationale  3 
2.1 Background Information  ................................ ................................ ..........................  3 
2.1.1  Oxfendazole  ................................ ................................ ................................  3 
2.1.2  Human Phase I Safety and Pharmacokinetics  ................................ .............  6 
2.2 Rationale  ................................ ................................ ................................ ................  6 
2.3 Potential Ri sks and Benefits  ................................ ................................ ...................  7 
2.3.1  Potential Risks  ................................ ................................ ............................  7 
2.3.2  Known Potential Benefits ................................ ................................ .............  8 
3 Objectives  9 
3.1 Study Objectives  ................................ ................................ ................................ ..... 9 
3.2 Study Outcome Measures  ................................ ................................ ......................  9 
3.2.1 Primary endpoint:  ................................ ................................ ........................  9 
3.2.2  Secondary endpoints:  ................................ ................................ ..................  9 
4 Study Design  10 
4.1 Substudies (if applicable)  ................................ ................................ ......................  [ADDRESS_685258] 
Administration  ................................ ................................ ...........................  17 
5.4.2  Handling of Withdrawals  ................................ ................................ ............  17 
5.5 Termination of Study  ................................ ................................ .............................  18 
6 Study Intervention/Investigational Product  [ADDRESS_685259] (Synanthic ® suspension) will be shipped from the DMID 
CAR to the study site upon request and approval by [CONTACT_122830].  
Formulation, Packaging, and Labeling ................................ .......................  [ADDRESS_685260] Storage and Stability  ................................ ................................ .... 19 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
v 6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  ................................ ................................ ................................ .................  20 
6.3 Modification of Study Intervention/Investigational Product for a Participant  ...........  20 
6.4 Accountability Procedures for the Study Interven tion/Investigational Product(s)  ... [ADDRESS_685261] Compliance with Study Intervention/Investigational 
Product  ................................ ................................ ................................ .................  21 
6.6 Concomitant Medications/Treatments  ................................ ................................ ... 21 
7 Study Schedule  22 
7.1 Screening (Day -28 to -1): Clinic Visit 00 ................................ ...............................  22 
7.2 Enrollment/Baseline - GROUPS 1, 2 and 3  ................................ ...........................  24 
7.3 Follow -up – GROUPS 1, 2 and 3  ................................ ................................ ..........  25 
7.4 Final Study Visit 08 – Day 10 (+/ - 2 days)  ................................ .............................  28 
7.5 Enrollment/Baseline - GROUP 4  ................................ ................................ ............  28 
7.6 Follow -up – GROUP 4  ................................ ................................ ..........................  29 
7.7 Final Study Visit 06 Day 14 (+/ - 2 days) - GROUP 4  ................................ .............  31 
7.8 Early Termination Visit  ................................ ................................ ..........................  31 
7.9 Unscheduled Visit  ................................ ................................ ................................ . 31 
8 Study Procedures/Evaluations  [ADDRESS_685262] 
Values or Abnormal Clinical Findings  ................................ ........................  37 
9.3 Reporting Procedures  ................................ ................................ ...........................  37 
9.3.1 Serious Adverse Events  ................................ ................................ ............  38 
9.3.2  Regulatory Reporting for Studies Conducted Under DMID -Sponsored 
IND ................................ ................................ ................................ ............  38 
9.3.3  Regulatory Reporting for Studies Not Conducted Under 
DMID -Sponsored IND  ................................ ................................ ...............  39 
9.3.4  Other Adverse Events (if applicable)  ................................ .........................  [ADDRESS_685263] Halting Rules  ................................ ................................ .. 39 
9.5.2  Dose Escalation Halting Criteria  ................................ ................................  40 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
vi 9.5.3  Study Halting Rules  ................................ ................................ ...................  40 
9.5.4  Individual Halting Rules  ................................ ................................ .............  41 
9.6 Safety Oversight (ISM plus SMC)  ................................ ................................ .........  41 
9.6.1  Independent Safety Monitor (ISM)  ................................ .............................  42 
9.6.2  Safety Monitoring Committee (SMC)  ................................ .........................  42 
10 Clinical Monitoring  43 
10.1  Site Monitoring Plan  ................................ ................................ ..............................  43 
11 Statistical Considerations  44 
11.1  Study Hypotheses  ................................ ................................ ................................ . 44 
11.2  Sample Size Considerations  ................................ ................................ .................  45 
11.3  Planned Interim Analyses (if applicable)  ................................ ...............................  46 
No interim analyses are planned.  ................................ ................................ ..........  46 
11.3.1  Safety Review  ................................ ................................ ...........................  46 
11.4  Final Analysis Plan  ................................ ................................ ...............................  46 
11.4.1  Populations for Analysis  ................................ ................................ ............  46 
11.4.2  Analysis of Demographics  ................................ ................................ .........  46 
11.4.3  Analysis of Safety  ................................ ................................ ......................  47 
11.4.4  Pharmacokinetic Analysis ................................ ................................ ..........  47 
12 Source Documents and Access to Source Data/Documents  49 
13 Quality Control and Quality Assurance  50 
14 Ethics/Protection of Human Subjects  [ADDRESS_685264]  ................................ ................................ ....................  51 
14.3  Informed Consent Process  ................................ ................................ ...................  51 
14.3.1  Informed Consent/Assent Process (in Case of a Minor)  ............................  52 
14.4  Exclusion of Women, Minorities, and Children (Special Populations)  ....................  [ADDRESS_685265] Keepi[INVESTIGATOR_007]  53 
15.1  Data Management Responsibilities  ................................ ................................ ....... 53 
15.2  Data Capture Methods  ................................ ................................ ..........................  53 
15.3  Types of Data  ................................ ................................ ................................ ....... 54 
15.4  Timing/Reports  ................................ ................................ ................................ ..... 54 
15.5  Study Records Retention  ................................ ................................ ......................  54 
15.6  Protocol Deviations  ................................ ................................ ...............................  54 
16 Publication Policy  56 
17 Literature References  57 
Appendix A: Schedule of Events  58 
Appendix B: DMID Adult Toxicity Tables Non -Serious Adverse Events  62 
Appendix C: GRADE THRESHOLDS FOR EKG  67 
Appendix D: University of Iowa Normal Laboratory Values  [ADDRESS_685266] Aspartate Aminotransferase  
AUC 0-t Area Under the Curve to the Final Sample  
AUC Area Under the Curve to Infinity  
CBER  Center for Biologics Evaluation and Research  
CDER  Center for Drugs Evaluation and Research  
CFR Code of Federal Regulations  
CL/F Oral Clearance  
Cmax Maximum Plasma Concentration  
CNS Central Nervous System  
CRF Case Report Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, 
DHHS  
eCRF  Electronic Case Report Form  
EKG Electrocardiogram  
FDA Food and Drug Administration  
FWA Federalwide Assurance  
GCP Good Clinical Practice  
GMP  Good Manufacturing Practice  
HIPAA  Health Insurance Portability and Accounting Act  
HIV Human Immunodeficiency Virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IV Intravenous  
λz Elimination Rate Constant  
LOQ Limits of Quantitation  
LLN Lower Limit of Normal  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NF National Formulary  
NEJM  New England Journal of Medicine  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
DMID [ADDRESS_685267] Level  
OCRA  Office of Clinical Research Affairs, NIH, DHHS  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
ORA Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS  
OXF Oxfendazole  
PHI Personal Health Information  
PI [INVESTIGATOR_527844]  
t1/[ADDRESS_685268] Upper Limit of Normal  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
VTEU  Vaccine Treatment and Evaluation Unit  
VZ/F Oral Volume of Distribution  
WHO  World Health O rganization  
  
  
  
  
  
  
  
  
  
  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
ix PROTOCOL SUMMARY  
 
Title:  A Phase  1, Open -Label,  Multiple Ascending Dose Study of 
Oxfendazole in Healthy Adult Volunteers   
Phase:  I 
Population:  Up to 3 6 healthy males and nonpregnant females, ages 18 -45, 
recruited from around Iowa City, IA  
Number of Site s: One site, the University of Iowa  
Study Duration:  Approximately [ADDRESS_685269] Participation 
Duration:  Approximately 6 weeks  
Description of Agent or 
Intervention:  Two to five oral doses of an aqueous suspension of 
oxfendazole, a benzimidazole carbamate antiparasitic drug  
Objectives : 
 Primary:  
• To assess the s afety of oxfendazole administered daily 
for five days  
• To assess the s afety of oxfendazole administered as a 
single dose with or without food  
Secondary:  
• To define the multi -dose kinetics of oxfendazole  
• To determine the effect of food on the kinetics of 
oxfendazole  
Description of Study 
Design:  This Phase I study is an open label evaluation of the safety and 
pharmacokinetics of escalating oral doses of oxf endazole ( 3 
mg/kg , 7.5 mg/kg or 15 mg/kg) given daily for five days in 
healthy volunteers. Up to eight volunteers will be enrolled and 
receive one oral dose of 3 mg/kg given daily for [ADDRESS_685270] will then be enrolled and followed for 7 days.  If no 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
x predefined safety events are identified, the remaining six 
subjects in this group  will be enrolled.  All volunteers will be 
follow ed for 10 days  and   pharmacokinetic, safety laboratory  
and EKG studies will be performed as outlined in the study visit 
table in Appendix A.  A safety review of the electronic data will 
be completed and the DMID Medical Monitor will receive a dose 
escalation report from the Statistical and Data Coordinating 
Center  (SDCC ) including whether dose escalation halt criteria 
were or were not met. I f no predefined safety events occur  after 
all eight subjects have  completed the day 10 v isit, the DMID 
Medical Monitor will issue approval to proceed with enrollment 
of the second group of eight subjects will be enrolled  to receive 
five days of 7.5 mg/kg of oxfendazole using the same enrollment 
plan as outlined above . If no predefined safety events are 
encountered, the third group  of eight subjects will be enrolled to 
receive five days of 15 mg/kg using the same enrollment plan. A 
fourth group of [ADDRESS_685271] for 8 hours and 
then will receive a single dose of 3 mg/kg of oxfendazole on day 
1.  The other half will receive a single dose of 3 mg/kg of 
oxfendazole following a h igh fat breakfast.  All [ADDRESS_685272]  and will be followed for another seven days.   
Pharmacokinetic studies w ill be performed for 24 hours following 
each dose of oxfendazole.  
Group  N Study Dose  Timing of Study Dosing  
1 8 3 mg/kg  Days 1 -5 
2 8 7.5 mg/kg  Days 1 -5 
3 8 15 mg/kg  Days 1 -5 
4 12 3 mg/kg  Days [ADDRESS_685273] (n=6) or high fat 
meal (n=6) on Day [ADDRESS_685274] 
on Day 8  
 
Estimated Time to 
Complete Enrollment:  12 months  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
xi *Schematic of Study Design :  
 
 
Consent and perform screening 
activities (Total  n = 24)
Enroll [ADDRESS_685275] ( 3 mg/kg daily x 5 days)
Follow for [ADDRESS_685276] ( 3 mg/kg daily x 5 days)
Follow for 7 days for PK and safety
If no safety signals , enroll 6 subjects        
(3 mg/kg daily x 5 days)
Follow for 10 days for PK and safety
 Safety review for entire group (n=8)
Screen and enroll group 2 using same 
strategy as above
(7.5 mg/kg daily x 5 days)
 Safety review for entire group (n=8)
Screen and enroll group 3 using same 
strategy as above
(15 mg/kg daily x 5 days)
Safety Monitoring Committee Review for 
Groups 1 , 2 and 3 (n=24)Day 1
n=6 to receive 3 mg/kg 
following a fast
n=6 to receive 3 mg/kg 
following a high fat breakfast
Follow for 7 days for PK and Safety
Day 8
n=6 to cross over to receive 
3 mg/kg following a high fat 
breakfast
n=6 to cross over to receive 
3 mg/kg following a fast
Follow for 7 days for PK and Safety
Consent and perform screening 
activities (Total  n = 12)
Multiple Dose Ascending 
Evaluation
Food Effects Evaluation
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
1 1 KEY ROLES  
Refer to ICH E6, Section 6.1  
(http://www.fda.gov/downloads/Drugs/Guidance/ucm073122.pdf ) 
For questions regarding this protocol, contact << insert name [CONTACT_527882]>> at 
<<NIAID/DMID (insert contact [CONTACT_3031])>>.  
 
Principal Investigator  [INVESTIGATOR_527843], MD  
University of Iowa  
University of Iowa Hospi[INVESTIGATOR_84059]  
[ADDRESS_685277]  
Iowa City, IA  [ZIP_CODE]  
Phone: 319 -384-1735  
Fax: 319 -335-8318  
E-mail: patricia -[EMAIL_10074]  
 
DMID Medical Monitor  Soju Chang, MD  
Office of Clinical Research Affairs (OCRA)  
DMID/ NIAID/ NIH  
[ADDRESS_685278], 7E59  
Bethesda ,  MD   [ZIP_CODE]  
Phone: 240 -292-4178 
E-Mail: [EMAIL_10075]  
 
DMID Scientific Lead  Greg Deye, MD  
CAPT, USPHS  
Medical Officer  
DMID/NIAID/NIH /PI[CONTACT_183075]  
[ADDRESS_685279], 8A39  
Bethesda ,  MD   [ZIP_CODE]  
Phone:       [PHONE_10931] 
E-Mail: [EMAIL_10076]  
 
DMID Clinical Project 
Manager  Effie Nomi cos, RN, MSN, CCRP  
Clinical Project Manager  
NIH/NIAID/DMID/PI[CONTACT_183075]  
5601 Fisher’s Lane, Room 8A35  
Bethesda , MD   [ZIP_CODE]  
Tel. 240 -627-3329 
Email:  [EMAIL_10077]  
 
DMID [ADDRESS_685280]:  Blossom T. Smith, MS  
Office of Regulatory Affairs (HNM5G)  
National Institute of Allergy & Infectious Diseases  
National Institutes of Health  
BG 5601FL RM 7F45  
Mail Stop [ADDRESS_685281]  
Bethesda, MD [ZIP_CODE]  
Tel: 240 -627-3376 
E-mail:  [EMAIL_10078]  
 
Statistical and Data 
Management Center  The E mmes  Corporation  
[ADDRESS_685282]., Suite 700  
Rockville, MD [ZIP_CODE]  
Phone: [PHONE_2269] 
Fax: 301 -251-1355 
 
Institutions:  University of Iowa  
 
  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
3 2 BACKGROUND INFORMATI ON AND SCIENTIFIC 
RATIONALE  
2.1 Background Information  
The three major soil transmitted helminthes, Ascaris lumbricoides  (roundworm), Necator 
americanus/Ancylostoma duodenale  (hookworms) and Trichuris trichiura  (whipworm ) are 
among the most prevalent parasites  worldwide.  They are highly prevalent in developi[INVESTIGATOR_527845].  It is estimated that these three helminths 
have an overall prevalence of one billion cases worldwide.  Nearly half of these cases result in 
signif icant morbidity especially af fecting young children ( 1).   Current control measures require 
the periodic administration of one of the four antihelminthics : mebend azole, albendazole, 
levamisole or pyrantel.  Of these drugs, the benzimidazoles (mebendazole a nd albendazole) are 
the most frequent ly used antihelminthics .  However, these drugs show varying efficacy against 
the array of human helminths.  Single oral doses of these compounds are highly effective 
against Ascaris lumbricoides , but have significantly less efficacy for hookworms and Trichuris 
trichiura  (2). 
 
Oxfendazole (OXF) is a potent, broad -spectrum antihelminthic drug that is approved and 
marketed for veterinary use.  Oxfendazole is currently marketed for use against lungworms and 
enteric helminths  in beef livestock. In humans, current benzimidazoles inclu de albendazole and 
mebendazole.  Though all of the benzimidazoles show chemical similarities, t he compound 
oxfendazole reaches peak blood levels more slowly following absorption from the intestinal tract 
than many other benzimidazoles, thereby [CONTACT_527857] a longer time 
in both the serum and intestinal tract .  This prolonged half -life is attractive for pursuing single 
dose therapy for certain helminths including  uncomplicated cysticercosis. However, even with 
this more prolonged half -life it is likely that extended therapy will likely be required for the  soil 
transmitted helminthes such as Trichuris trichiura and hookworm infections .  Given th e 
potentially favora ble pharmacokinetics , oxfendazole is an attractive compound for transition to 
human use  and animal and human studies outlined below have begun to define the safety and 
pharmacokinetic parameters  of this compound .   
2.1.1  Oxfendazole  
[IP_ADDRESS]  Structure and Formulation  
Oxfendazole, or [5 -(phenylsulphinyl) -1H-benzimidazole -
2-yl]carbamic acid methyl ester (Sy nanthic®), was first 
identified in the laboratories of Syntex Research, Palo 
Alto, [LOCATION_004], and shown to have anthelminthic 
properties against larval and adult forms of 

DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
4 gastrointestinal cestodes and nematodes in various animal species (3). The structure consists 
of the benzimidazole carbamate characteristic of this group of drugs, with a phenylsulphinyl 
substituent in position 5 (4). Oxfendazole (Synanthic®) is formulated as  an aqueous suspension 
of either 9.06% or 22.5%, manufactured by [CONTACT_527858].  At the current 
time, only the 22.5% formulation is available, though production of the lower concentration may 
return in the future.    
The introduction of thiabendazole as the first benzimidazole anthelminthic in the early 1960s 
provided a significant advance in veterinary antiparasitic treatment (7). However, thiabendazole 
has a short biological half -life, due to rapid hydro xylation of the 5 ( 8) position of the 
benzimidazole ring and extensive urinary clearance (9). Further efforts were directed toward the 
production of compounds with a variety of substitutions in this metabolically labile position, 
leading to different pharmacological behavior, and increased potency and spectrum of 
antiparasitic activity (10). The more potent later generations of benzimidazoles include 
fenbendazole, oxfendazole, and albendazole, with efficacy against roundworms, tapeworms, 
and even parasites residing outside the gastrointestinal tract (11). Thiabendazole, mebendazole 
and albendazole are currently approved and marketed in the US for treatment of helminth 
infections in humans.  
[IP_ADDRESS]  Mechanism of Action  
Benzimidazoles appear to have multiple mol ecular mechanisms of action. They interfere with 
bioenergetics in the parasite by [CONTACT_527859], as well as restricting glucose uptake (11). They also alter the tubulin -microtubule 
equilibrium, by [CONTACT_527860] (12). Inhibition of tubulin 
polymerization induces disintegration of the microtubular network in parasites (13).  
[IP_ADDRESS]  Prediction of Human No Effect Dose from Chronic Toxicology  
and Carcinogenicity Studies  
No effect dose in chronic preclinical toxicology studies  
Oxfendazole has been evaluated in numerous safety and toxicology studies in ruminants as well 
as in more traditional preclinical species.  The results of the most important chronic toxicology 
studies, with doses adjusted for surface area, are summarized and projected to human doses 
below.  
 
Table 1.   Calculated no effect dose in humans based on  outcomes from preclinical 
toxicology studies  
Species  Study  No Effect Dose  
Preclinical toxicology studies  Calculated 
adult 
human 
equivalent  
mg/kg/day  Syntex 
study 
number (21) mg/kg/day  mg/m2/day 
DMID [ADDRESS_685283] Dose  
Mouse  18 mo 
carcinogenicity  66-M-84 150 375 9.91 
      
Rat 1 yr chronic toxicity  101-R-74 0.7 4.73 0.13 
2 yr carcinogenicity  53-R-83 0.7 4.73 0.13 
Dog 1 yr chronic toxicity  18-D-84 13.5 265 7.00 
Rat 14 d sub -acute 
toxicity  xxx 5  0.8 
Mouse  Single dose  xxx 6400  512 
Rat Single dose  xxx 3200  512 
Dog Single dose   1600  864 
 
[IP_ADDRESS]  Animal Safety  
The potential cardiovascular or toxicity effects of oxfendazole (OXF) were investigated after 
drug administration to beagle dogs (14).  Following administration of single oral doses of 
oxfendazole at 0, 5, 25 or 100 mg/kg, no changes in body weight, body temperature, clinical 
laboratory evaluation s (hematology, serum chemistry, and coagulation studies), changes in vital 
signs (blood pressure, heart rate) or changes in electrocardiogram evaluations were noted.  
A two week toxicology study of oxfendazole administered orally to rats at doses from 0 -200 
mg/kg, was recently performed ( 15).  There were no changes in feeding, behavior or 
physiological measurements (15).  Animals in the highest dose groups were euthanized on day 
8 because of severe toxicity and mortality.  Females had a higher incidence of mortality and 
more severe adverse effects than did males administered the same dose; correspondingly 
higher OXF exposure was found in females than in males. At the higher doses, WBC depletion 
was dose related, being severe in females at the highest dose.  WBC recovered when OXF 
administration was suspended. Target organs of toxicity were bone marrow, epi[INVESTIGATOR_4046], liver, 
spleen, testis and thymus.  Hepatic midzonal fatty change was present in male and female rats 
administered the higher doses; these changes were still pres ent after a 14 -day recovery period. 
However, no effects on liver enzymes were seen in the clinical chemistry results, suggesting 
that these effects did not result in overt hepatotoxicity or compromised hepatic function; 
therefore, the toxicologic significa nce of this observation is unclear.  
Several toxicology studies were performed at the time of Synanthic® approval.  In single dose 
toxicology studies in mice, rats and dogs.  One rat that received a dose of 6400 mg/kg, orally 
died from enteropathy.  In subc hronic toxicology studies in which rats and dogs were dosed 
over a two week period at doses ranging from 11 -200 mg/kg, orally, decreases in neutrophil 
count, hemoglobin and hematocrit were seen at the higher doses, as were pathological changes 
in the liver  (with hepatocyte vacuolation), gastroenteropathy, testes, bone marrow, liver, spleen, 
and thymus.  Toxicology studies demonstrated mild hepatotoxicity in rats fed 2.1 or 7 mg/kg 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
6 daily for a year (16).  Similar dog studies showed no toxicity (16).  Fetotoxicity was noted in rats 
and mice (16).  
2.1.2  Human Phase I Safety and Pharmacokinetics  
A recent dose escalation study has been performed evaluating 70 healthy adult men and 
women of non -child bearing potential who were age 18 -45 ([STUDY_ID_REMOVED], DMID 12 -0053, 
unpublished) . Seven dose groups were studied (0.5, 1, 3, 7.5, 15, 30 and 60 mg/kg) and each 
dose group was comprised of [ADDRESS_685284] with an increased PR interval 14 days following the 
dose of  study drug, and the remaining events were gastrointestinal events (nausea, loose 
stools, intestinal gas, and diarrhea, all of which occurred in the 30 or 60 mg/kg dose groups.  
There was one event, a sore throat that was considered moderate in intensity.  Mild to moderate 
laboratory events were seen in hematology and chemistry tests.  There were no patterns 
identified  related to timing of the abnormal laboratory studies or dose of oxfendazole  and the 
placebo group had similar rates of abnormal laboratory v alues.   
The median time of maximum concentration (T max) occurred at 2 hours and the geometric mean 
maximum concentration (C max) ranged from 943.9 -6768.4 ng/mL.  The exposure was non -linear, 
plateauing at 15 mg/kg.  The half-life (t 1/2) was consistent between groups and ranged from 8.5 -
11 hours.  The overall fraction of drug excreted in the urine was very low and the geometric 
mean AUC 0-t for the sulfone metabolite was 11.5 -15% of oxfendazole AUC 0-t while fenben dazole 
AUC 0-t was less tha n 1% of oxfend azole AUC 0-t for each dose group.  
2.[ADDRESS_685285] or following a high fat 
meal.    
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
7 2.3 Potential Risks and Benefits  
2.3.1  Potential Risks  
 
Oxfendazole has been studied in a single human phase I trial in doses that  are similar to those 
proposed in this study.  Seventy healthy adults were evaluated in a dose escalation trial where 
each individual received a single dose of oxfendazole with dosage levels ranging from 0.5 to 60 
mg/kg.  The drug was well tolerated though  a few subjects experienced mild gastrointestinal 
symptoms (mild nausea and short duration diarrhea) seen on the day of dosing in the 30 mg/kg 
and 60 mg/kg dosage levels.  One individual had a grade [ADDRESS_685286] been associated with liver abnormal ities and bone marrow 
suppression. Albendazole  has also been associated with headache, gastrointestinal side effects 
(abdominal pain and nausea) in less than 10 % of subjects as well as rare allergic reactions 
(rash, urticaria, Stevens -Johnson syndrome) in  less than 1 %.  
 
In animal studies, lower OXF doses and shorter periods of administration similarly result in no 
observable toxicity.  At higher doses, the principal target organs are bone marrow and liver, 
WBC count rapi[INVESTIGATOR_527846].  
In animal studies, fetotoxicity was reported and changes in the testes were seen.  
 
Subjects will be closely monitored by [CONTACT_969], physical examination and laboratory tests to 
assess safety and tolerability. Subjects will be carefully monitored for AEs and blood studies will 
be monitored to assess for any changes in the complete blood counts, liver and renal function 
and coagulation factors. As for any experimental drug, there may be side effects of oxfendazole 
that are not presently kn own. EKG studies will be performed to assess for cardiac effects.  
 
Men will be counseled to use condoms and women will be counseled to avoid pregnancy 
attempts for 4 months following drug administration. It is unknown if Oxfendazole  pose any risks 
to an un born child.   
 
There are no significant side effects from electrocardiogram (EKG) other than cosmetic 
annoyance from the glue employed to hold the leads. Venipuncture can result in pain or 
discomfort, and less likely, the possibility of bruising, or infecti on at the site, or fainting. Loss of 
confidential health information could occur.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
8 Subjects will be asked to provide personal health information (PHI).  All attempts will be made to 
keep this PHI confidential within the limits of the law.  However, there i s a chance that 
unauthorized persons will see the subjects’ PHI.  All records will be kept in a locked file cabinet 
or maintained in a locked room at the participating VTEU sites.  Electronic files will be password 
protected.  Only people who are involved in the conduct, oversight, monitoring, or auditing of 
this study will be allowed access to the PHI that is collected.  Any publications from this study 
will not use information that will identify subjects by [CONTACT_2300]. Organizations that may inspect 
and/or copy  research records maintained at the participating VTEU sites for quality assurance 
and data analysis include groups such as: National Institute of Allergy and Infectious Diseases 
(NIAID) and Food and Drug Administration (FDA). There may be other unknown si de effects.  
2.3.[ADDRESS_685287]  societal benefits as knowledge about new antiparasitic  agents could help 
in the creation of new drugs for difficult to treat helminthic infections.  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
9 3 OBJECTIVES  
3.1 Study Objectives  
Primary:  
• To assess the safety of oxfendazole administered daily for five days  
• To assess the safety of oxfendazole administered as a single dose with or without food  
Secondary:  
• To define the multi -dose kinetics of oxfendazole  
• To determine the effect of food on the kinetics of oxfendazole  
3.2 Study Outcome Measures  
3.2.1   Primary endpoint : 
 
• The rate of adverse events (AEs) related to oxfendazole within 10 days of 
receipt of oxfendazole given for 5 sequential, daily  oral dose s of either  3, 
7.5 or 15 mg/kg  
 
• The rate of  adverse events (AEs) related to oxfendazole within 7 days of 
receipt of o xfendazole given as a single daily dose of 3 mg/kg on days [ADDRESS_685288] or following a high fat meal.  
 
3.2.2  Secondary endpoints:  
• Plasma Cmax, Tmax, AUC, T 1/2 of oxfendazole at specified time points 
following each dose of a 5 day daily regi men of either 3, 7.5 or 15 
mg/kg  
• Plasma Cmax, Tmax, AUC, T 1/2 of oxfendazole at specified time points 
following a single dose of oxfendazole of 3 mg/kg on days [ADDRESS_685289] or after a high fat meal.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
10 4 STUDY DESIGN  
This Phase I study is an open label multiple ascending dose evaluation of the safety and PK of 
oxfendazole ( 3, 7.5, or 15 mg/kg) in healthy adult men and nonpregnant women aged 18 -45 
(inclusive) followed by a single dose cross over trial evaluating the safety and pharmacokinetics 
of a single dose of oxfendazole (3 mg/kg) given following an [ADDRESS_685290] or following a high fat 
meal. In the multiple ascending dose evaluat ion, each dose group will be comprised of eight  
volunteers.  In the food effects evaluation, evaluating the effects of food on drug absorption, 12 
subjects will be enrolled into the single dose cross over group  where half of the subjects will 
initially receive a single dose of 3 mg/kg of oxfendazole following an [ADDRESS_685291] and the other 
half will receive a single dose of 3 mg/kg of oxfendazole following a high fat meal . Subjects will 
then cross over to receive a single dose following a high fat breakfast o r fasting period  (water is 
permitted) .  All subjects will have received a single dose of oxfendazole  (3 mg/kg)  following both 
a fasting period and a meal.   
 
For the multiple ascending dose evaluation , each subject in the first dose group (3 mg/kg ) will 
receive an oral daily dose of oxfendazole for five sequential days and will  be monitored for a 
total of [ADDRESS_685292] no t been met. I f none of the predefined safety events  
(any study drug related SAE, any study drug related Grade [ADDRESS_685293] occurred  (one study drug related  two sequential subjects  (one at a time with [ADDRESS_685294])  DMID will approve enrollment into the second dose group (7.5 
mg/kg  oxfendazole  daily x 5 days)  and will be monitored for a total of [ADDRESS_685295] occurred  two sequential subjects  (one at a time with [ADDRESS_685296])  will be enrolled into the third  dose group (15 mg/kg  oxfendazole  daily x 5 days)  
and will be monitored for a total of 7 days  each  for predefined safety  events prior to enrolling the 
remaining subjec ts in the group.  
 
 
For the multiple ascending dose evaluation , between 8 and 24 subjects will be enrolled. This 
number should be small enough to perform the study safely and efficiently, yet large enough for 
an estimation of the oxfendazole PK and the identification of any common side effects of 
oxfendazole  following multiple doses . 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
11   
During the screening process written informed consent will be obtained prior to any study 
activities.  A complete medical history will be obtained including review of medications, 
supplements and vitamins. Vital signs including oral temperature, blood pre ssure, pulse, height, 
weight and an EKG will be performed and a routine physical exam will be performed by a 
licensed clinician. Laboratory tests for hemoglobin, white bloo d cell count with neutrophil , 
platelet count, creatinine, alanine aminotransferase ( ALT), aspartate aminotransferase (AST), 
total bilirubin, random glucose, urine dipstick for protein and glucose, INR and partial 
thromboplastin time (PTT), hepatitis B surface antigen, hepatitis C antibody, and human 
immunodeficiency virus serology (HIV). Eligible subjects will be invited to join the study.  They 
will be advised to abstain from drug or alcohol use for the 48 hours prior to return on Day 1 and 
to avoid tobacco use from the day of screening through the end of the study.  
 
On study day 1 , a rev iew of the inclusion/exclusion criteria will be conducted with subjects  and 
vital signs, including oral temperature, blood pressure and pulse will be obtained .  A review of 
medication history since the screening visit  will be obtained  and a physical exam w ill be 
performed by a licensed clinician.   Blood will be drawn for baseline PK and safety laboratory 
tests (hemoglobin, white blood cell count with  neutrophil , platelet count, creatinine, Na, K, Cl, 
CO 2, blood urea nitrogen, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
INR and PTT, total bilirubin, and urine dipstick for protein and glucose).   
Subjects will be administered oxfendazole  by a study nurse or investigator  on days 1, 2, 3, 4 
and 5. Subjects will be fasting (water is permitted)  for eight  hours prior to, and for two hours 
after, the administration of drug.  On the 1st and 5th day of drug administration  intensive blood 
sampling will be performed for PK studies ( pre-dose and 30 minutes,  1, 2, 3, 4, 6, 9, and 12 
hours following the dose) .  On days 2, 3 and 4, blood sampling  for PK studies  will be performed 
prior to each dose and 2 hours after each dose . On day 6, blood sampling for PK studies will be 
performed approximately 24 hou rs following the dose on day 5. Monitoring will start immediately 
after dosing and will continue for 10 days .  Safety laboratories will be performed on days 1, 3, 5, 
8 and 10.  EKG studies will be performed at screening , two hours after doses on days 1, 3 and 
5, and day 8 .  Subjects will be interviewed to monitor for AEs and SAEs.  Blood sampling for PK 
studies will be performed on days 8 and 10. In addition, prior to study drug administration on 
days 2 -5, if subjects self -report  any new signs or symptoms a  targeted physical exam may be 
performed , if indicated , and the new signs or symptoms will be recorded as an AE or SAE as 
appropriate.  
 
Following blood sampling performed on each day of dosing,  subjects will be allowed to return 
home.  Subjects will be counseled to avoid drug, alcohol and tobacco use through the end of the 
study ( Day 10 for groups 1-3 and Day 14 for group  4).  
 
In the food effects evaluation , 12 subjects will be enrolled into th e single dose cross over group . 
Group 4 can be enrolled concurrently with groups 1, 2, and 3.  In group 4, half of the subjects will 
receive a single dose of 3 mg/kg of oxfendazole following an [ADDRESS_685297] will be followed with safety 
laboratories, EKGs and PK studies for 7 days at which time they will cross over to receive a 
single dose of oxfendazole  (3mg/kg) following either a high fat meal or following an [ADDRESS_685298] EKG studies will be performed at screening, and two hours after dos ing on 
days 1 and 8.  Safety laboratories will be perfor med on day 1, 4 and  14.  Blood sampling for PK 
studies will be performed (pre-dose and 30 minutes, 1, 2, 3, 4, 6, 9, 12 and 24 hours following 
each  dose  and on day 14).  
  
The study will be conducted on an outpatient basis at the University of Iowa. Screening for 
subject recruitment will continue throughout the study until the requisite number of volunteers is 
enrolled. Each subject will be evaluated over a [ADDRESS_685299] 
participation will be 3 -6 weeks of face -to-face visits, including the screening period.  It is 
anticipated that it will take 12 months to finish the study.   
 
 
4.1 Substudies (if applicable)  
No substudies are planned  
DMID [ADDRESS_685300] previously participated in trials conducted at the participating VTEU sites.  
Other forms and/or mechanisms of recruitment may also be used.   
The University of Iowa IRB will approve all methods of recruitment and recruitment materials 
prior to use.   
The initial responders will be screened by [CONTACT_527861]. Successful candidates will be asked to come to 
the clinic to further assess their eligibility.  
Subject Inclusion and Exclusion Criteria must be assessed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA [ADDRESS_685301] Inclusion/Exclusion Criteria in DMID - sponsored studies. 
Questions  about eligibility should be directed toward the DMID Medical Officer.  
 
5.[ADDRESS_685302] meet all of the following inclusion criteria to participate in this study:  
1. Males and nonpregnant females between the ages of 18 and 45 years, inclusive.  
 
2. Women of childbearing potential* must agree to practice adequate contraception** for the 
28-day period before Day [ADDRESS_685303] dose of study medication .  
 
* A woman is considered of childbearing potential unless surgically sterile (tubal ligation, bilateral 
oophorectomy, or hysterectomy) or post-menopausal ( ≥1 year). 
 
**Acceptable birth control methods include but are not limited to: abstinence from sexual intercourse 
with men; monogamous relationship with a vasectomized partner; double -barrier methods 
(condoms, diaphragms, spermicides); intrauterine devices; and licensed hormonal methods.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
14 1. In good health, as judged by [CONTACT_527862] b y vital signs*  
2. *Temperature < 38°C, heart rate ≤ 100 bpm and > 50 bpm, systolic blood pressure ≤ 140 
mmHg and > 89 mmHg, diastolic blood pressure ≤ 90 mmHg and ≥ 60 mm Hg, medical 
history and a targeted physical examination.  BMI ≥18 and ≤ 35.  Athletical ly trained 
subjects with a pulse ≥ 45 may be enrolled at the discretion of the principal investigator [INVESTIGATOR_527847] . Acceptable screening laboratories*  
 
*Hemoglobin, white blood cell (WBC) count, neutrophil, and platelet cou nts, INR and PTT  
within normal ranges. AST < 44 and ALT < [ADDRESS_685304] be equal to 
or below the upper limit of normal (creatinine values below the normal range are 
acceptable). Random blood glucose must be <140. Urine dipstick te sting must be negative 
for glucose and negative or trace for protein. The following serology tests must be negative: 
HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.  
HIV and hepatitis C viral load PCR testing ma y be performed for individuals suspected of 
having indeterminate antibody testing.  
3. Male participants must be willing to ensure use of condoms and spermicides for [ADDRESS_685305] agree to abstain from drug or alcohol use for 48 hours prior to enrollment 
through day 1 0 or 14 . 
7. Able to provide a home phone number, and the name, address, and/or email of a person 
willing to assist with making contact [CONTACT_527863] -up phase of the study.  
 
5.[ADDRESS_685306] Exclusion Criteria  
Subjects who meet any of the exclusion criteria at Screening/Bas eline will be excluded from 
study participation. Exclusion criteria must be assessed by a clinician licensed to make medical 
diagnoses. Subjects will not be able to participate if they have any of the following:  
1. Pregnant  women , women who are planning to be come pregnant in the next 4 months,  or 
women who are breastfeeding.  
2. Body temperature ≥100.4°F (≥38.0°C) or acute illness within 3 days before administration 
of study drug (subject may be rescheduled).  
3. Chronic or acute medical disorder*  
*Disorders of the cardiac, pulmonary, liver, kidney, neurologic, gastrointestinal or other 
system, such that in the opi[INVESTIGATOR_527848], or to the validity of the study.  
4. Use of chronic systemic medications*   
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
15 *Intermittent use of over the counter medications such as acetaminophen, ibuprofen, cold 
and sinus medications are permitted for enrollment (please see section 6.6 for instructions 
on medication use during the study).  Topi[INVESTIGATOR_5910], nasal steroids are permitted 
throughout the study.  Use of prescription medications used less than once per week on 
average are permitted for enrollment (see section 6.6 for instructions on medication use 
during the study).  If the su bject has taken a short term prescription medication within the 
past 30 days (e.g. an antibiotic), they should be postponed from enrollment until [ADDRESS_685307] dose.  
5. Has history of sensitivity to related benzimidazole compounds (e.g. , albendazole, 
mebendazole).  
6. A diagnosis of schizophrenia, bipolar disease, or history of hospi[INVESTIGATOR_272] a psychiatric 
condition or previous suicide attempt.  
7. A history of treatment for any other psychiatric disorder in the past 3 years.*   
*Past trea tment for ADHD does not exclude participants from enrollment as long as the 
medications have been discontinued for a minimum of 3 months and symptoms are well 
controlled.   
8. Received an experimental agent* within [ADDRESS_685308] to receive an experimental agent during the 1 0 or 14 -day study period.  
*Vaccine, drug, biologic, device, blood product, or medication.  
9. Any condition that would, in the opi[INVESTIGATOR_871], interfere with the study.*  
*This includes any condition that would place them at an unacceptable risk of injury, render 
them unable to meet the requirements of the protocol, or that may interfere with successful 
completion of the study.  
10. A history of heavy alcohol * or illicit drug u se†, or history of substance abuse#.  
*On average , greater than 7 alcoholic drinks per week. .  
†Other than occasional marijuana use (less than once per week for the past 60 days is 
acceptable).  
#Alcohol or illicit drugs within the past [ADDRESS_685309] 60 days.*  
*A history of occasional tobacco use (less than 1 pack per week on average) is acceptable.  
Individuals will be counseled to abstain from use of tobacco and marijuana from screening 
through day 1 0 or 14 .   
Vital signs may be performed up to three times to allow for transient conditions to resolve.  
Screening laboratory values that are abnormal, but are considered to be abnormal due to an 
acute illness or process may be repeated once. Creatinine values that f all below normal values 
specified in the DMID Toxicity Table are not considered abnormal for the purposes of this study.  
Additionally, abnormalities in the RBC parameters other than hemoglobin and abnormalities in 
the WBC differential not specified in the  inclusion criteria above (e.g. low basophils or 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
16 eosinophils) will not be considered exclusionary for this study and will be followed with the 
standard safety laboratory follow -up outlined in the  protocol .  Laboratory values that are 
performed as a standar d panel by [CONTACT_20019], but are not requested for the study, will 
be reviewed by a licensed study clinician and the clinician will determine whether the laboratory 
abnormality is clinically significant and should be considered exclusionary. If determined to be 
clinically insignificant, the study team is not required to follow the laboratory until resolution or 
the value is determined to be clinically stable.  
5.3 Treatment Assignment Procedures  
 
5.3.1  Enrollment and Randomization Procedures  
Per International Conference on Harmonisation (ICH) guideline E6: Good Clinical Practice  
(GCP), screening records will be kept at the participating site to document the reason why an 
individual was screened, but failed trial entry criteria. The reasons why ind ividuals failed 
screening will be recorded in the S DCC’s  AdvantageEDCSM (Electronic Data Capture system).  
 
Once consented, the subject will be enrolled by [CONTACT_527864]. This is an open label study and subjects will be enrolled sequentially into 
groups 1, [ADDRESS_685310] 
been entered into the system.  
All participants in group 4 will receive oxfendazole in  two conditions: after a high -fat breakfast 
and after fasting  (separated by [CONTACT_185883]).  The order of condi tions will be randomly assigned  
upon enrollment  in a 1:[ADDRESS_685311] is randomized and 
enrolled, AdvantageEDCSM will generate a treatment assignment number.  
 
Instructions for use of the enrollment module are included in the AdvantageEDCSM User’s  
Guide. Manual back -up procedures and instructions are provided for use in the event that the 
site temporarily loses acces s to the Internet or the online enrollment system is unavailable.  
  
5.3.[ADDRESS_685312] may withdraw or be withdrawn from the study for the following reasons:  
• Medical disease or condition, or any new clinical findings for which  continued 
participation, in the opi[INVESTIGATOR_29352] -
investigator, would compromise the safety of the subject, or would interfere with the 
subject's successful completion of the study, or would interfere with the e valuation of 
responses.  
• Subject no longer meets eligibility criteria.  
• As deemed necessary by [CONTACT_16541] [INVESTIGATOR_29353] -
investigator for noncompliance or other reasons.  
• Subject withdrawal of consent.  
• Subject lost to follow -up. 
• Termi nation of the study.  
• New information becomes available that makes further participation unsafe.  
If a subject withdraws or is withdrawn prior to completion of the study, the reason for this 
decision must be recorded in the case report forms (CRFs).  Refer t o Section 7.[ADDRESS_685313] will continue with safety monitoring through the completion of the study.   
 
5.4.2  Handling of Withdrawals  
The primary reason for withdrawal from the study will be recorded on the Study Status data  
collection form.  Subjects will be encouraged to complete the Early Termination Visit.  The Early 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
18 Termination Visit procedures are listed in Section 7.8.  Although subjects are free to withdraw at 
any time or may be withdrawn by [CONTACT_527865]-investigator  at 
any time, subjects who receive study drug will be encouraged to remain in the study for follow -
up safety assessments and collection of venous blood samples for safety testing.  Every attempt 
will be made to follow a ll adverse events, including systemic reactions, serious adverse events, 
ongoing at the time of early withdrawal to resolution.  
In the case of subjects who fail to appear for a follow -up safety assessment, extensive effort 
(i.e., three documented contact a ttempts via phone calls, e -mails, etc., made on separate 
occasions and followed by a certified letter) will be made to locate or recall them, or at least to 
determine their health status.  These efforts will be documented in the subject’s records.  
Subjects  who withdraw, or are withdrawn or terminated from the study, or are lost to follow -up 
after signing the informed consent form, randomization, and receipt of [ADDRESS_685314] vomits more than two 
doses (i.e. if vomiting occurs within [ADDRESS_685315] vomits 
on two days or more ), the subject will be replaced.  Additionally, if the subject  vomit s within [ADDRESS_685316] will be replaced.  
 
5.5 Termination of Study  
The NIAID/DMID has the right to terminate this study at any time.  Reasons for terminating the 
study may include, but are not limited to, the following:  
• Incidence or severity of AEs indicating a potential health hazard  
• Data recording is inaccurate or incomplete  
• The Investigator has not been adhering to the protocol or applicable regulatory 
guidelines in conducting the study  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
19 6 STUDY INTERVENTION/I NVESTIGATIONAL PRODU CT 
6.[ADDRESS_685317] Description  
Oxfendazole, methyl -5 (6)-phenylsulfiyl -2-benzimidazole carbamate, is a broad spectrum 
benzimidazole antihelminthic.  It is the sulphoxide metabolite of fenbendazole.  Oxfendazole is 
marketed for cattle in  the [LOCATION_002] as SYNANTHIC®. 
6.1.[ADDRESS_685318] (Synanthic ® suspension)  will be purchased through a commercial supplier .  
 
Upon request by [CONTACT_122830], the investigational product will be shipped to the following address:  
 
DMID -Clinical Agents Repository (CAR)  
Fisher BioServices  
[ADDRESS_685319]  
Germantown, MD [ZIP_CODE]  
Tel: (240) 477 -1350  
Fax: (240) 477 -1360  
Email: [EMAIL_10079]  
 
 
6.1.[ADDRESS_685320] ( Synanthic ® suspension ) will be shipped from the DMID 
CAR to the study site upon request and approval by [CONTACT_122830].  
Formulation, Packaging, and Labeling  
Oxfendazole is formulated as  a white to grey powder; insoluble in water, slightly soluble in 
acetone, chloroform, ether, and methanol. The study product will be supplied as  the commercial 
veterinary product Synanthic ®, which consists of an aqueous  suspension in the following 
strength:  225 mg/ mL (5).   
6.1.[ADDRESS_685321] Storage and Stability  
Oxfendazole should be stored at room temperature (20º - 25º C) though excursions between 15º 
and 30ºC for less than 24 hours are acceptable.  
 
 
 
 
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
20 6.2 Dosage, Preparation and Administration of Study 
Intervention/In vestigational Product  
6.2.1 Dosage  
Oxfendazole   
In Groups 1 -3, subjects will receive a total of five oral doses (3 mg/kg, 7.5 mg/kg or 
15mg/kg ), given daily for 5 days (Study Days 1 -5). In Group 4, subjects will receive a 
total of two oral doses of 3 mg/kg , given on Study Days [ADDRESS_685322] will be orally administered vial oral dosing syringe (s). 
6.3 Modification of Study Intervention/Investigational Product for a 
Participant  
No modifications of study p roduct dosing are planned  at this time . 
6.4 Accountability Procedures for the Study 
Intervention/Investigational Product(s)  
 
After recei pt of study products, the site Principal I nvestigator  (PI) is responsible for distribution 
and disposition  of the study product , and has ultimate responsibility for study product 
accountability.  The site PI [INVESTIGATOR_527849] (or designee). 
The site pharmacist (or designee) m ust maintain study product records and document l ogs of 
receipt, accountability, and storage temperature  conditions. These study product accountability 
and dispensing logs must be maintained in the study file.  Upon completion of the study and 
after the fi nal monitoring visit, unused study product will be retained until monitored and 
released for disposition, as applicable. Final disposition of the unused study product will be 
determined by [CONTACT_527866].  
 
DMID [ADDRESS_685323] Compliance with Study 
Intervention/Investigational Product  
Oral intake of the study product by [CONTACT_527867].  Subjects 
will be provided the dose in an oral dosing syringe.  Immediately following administration of the 
dosethe subject will drink [ADDRESS_685324] will continue to be followed for safety and 
pharmacokinetic analyses.  
 
6.6 Concomitant Medications/Treatments  
It is the goal of this study to enroll subjects who are healthy and on n o chronic medications.  
Subjects will be counseled to refrain from taking prescription medications other than topi[INVESTIGATOR_527850] .  If a prescription is authorized by [CONTACT_527868], we wil l counsel them to discuss the medication with the study 
team prior  to starting the medication.   One of the licensed clinical providers from the study team 
will help determine whether the prescription medication can be postponed until the study is 
complete d. Additionally, subjects will be counseled to avoid all over the counter medications 
unless absolutely necessary and will be asked to consult with a study investigator prior to use of 
over the counter medications.  Subjects will be counseled to avoid acet aminophen since this 
medication can be associated with hepatotoxicity.   
Administration of any medications, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
data collection form.  Concomitant medications will include all current medications and 
medications taken within [ADDRESS_685325] day 
of the study visit schedule .  Prescription and over -the-counter drugs will be included as well as 
vitamins and supplements.  
Use of new medication should prompt evaluation for the presence of a new diagnosis of chronic 
medical disease or chronic medical condition.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
22 7 STUDY SCHEDULE  
7.1 Screening (Day -28 to -1): Clinic Visit 00 
Informed Consent.  Written informed consent will be obtained prior to any other study 
procedures.  
Assessment of Eligibility Criteria including:  
Medical History.   A complete medical history will be obtained by [CONTACT_468460] .  
Emphasis will be placed on the absen ce of significant medical or psychiatric illness and the 
absence of recent illness and recent or current medication, except use of over the counter or 
prescription medications that are taken on average less than once per week.  
 
Physical Examination.  
• A routine physical examination that assesses general appearance and the following 
areas/systems, including skin, lymph nodes, HEENT, neck, respi[INVESTIGATOR_696], cardiovascular, 
pulmonary, abdomen, extremities, musculoskeletal, and neurological will be performed 
by a clinician licensed to make diagnoses.  
• Height, weight, vital signs including oral temperature, blood pressure, and pulse will be 
obtained.  
 
Obtain 15 mL of blood for the following studies:  
• Hematology: Hemoglobin, white blood cell count with neutrophil count, platelet count.  
• Coagulation Studies:   INR and partial thromboplastin time (PTT)  
• Chemistry : Creatinine, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), random glucose and total bilirubin will be used as screening tests.  
• Serology : Hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency 
virus (HIV). If the subject tests positive for HIV or Hepatitis, they will be referred for 
medical follow -up and counseling.  
Obtain urine sample for:  
• Urine analysis : Urine dipstick for protein and glucose  
• Urine pregnancy test : for females of childbearing potential.  
 
EKG.   Perform [ADDRESS_685326]:  
• Abstain from taking medications, recreational drugs or engaging in alcohol intake [ADDRESS_685327] and through Day 1 0 or 14 . 
• Abstain from tobacco use from the time of screening through Day 1 0 or 14 . 
• Fasting (water is permitted)  [ADDRESS_685328]  (except 
subjects in the fourth  group who are to receive study product following a high fat meal.  
DMID [ADDRESS_685329] )  
• Counseling on avoidance of pregnancy . 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
24 7.2 Enrollment/Base line - GROUPS 1 , 2 and 3 
Clinic Visit 01, Day 1   
Eligible subjects will be asked to return to the Clinical Research Unit (CRU) having fasted for 8 
or more hours.  
 
General.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food intake  
and laboratory results obtained at the screening visit, Day 00 ). 
• Absence of medications in the past 48 hours will be confirmed.  
• A brief interim medical history will be taken.  
• A routine physical examination that assesses general appearance and t he following 
areas/systems, including skin, lymph nodes, HEENT, neck, respi[INVESTIGATOR_696], cardiovascular, 
pulmonary, abdomen, extremities, musculoskeletal, and neurological will be performed 
by a clinician licensed to make diagnoses.  
• Vital signs including oral t emperature, blood pressure, and pulse will be obtained.  
• Perform a urine pregnancy test for female subjects of childbearing potential.  
• A heparin lock will be inserted, blood will be drawn (10 mL) for baseline PK ( prior to 
product administration), and (15 m L) for safety labs (hemoglobin, white blood cell count, 
including neutrophil count, platelet count, INR, partial thromboplastin time, creatinine, 
Na, K, CL, CO 2, blood urea nitrogen, ALT, AST, and total bilirubin . 
• Collect urine for  dipstick  testing for protein and glucose   
• Enter subject into electronic data entry system.  
    
Administration of Study Medication  
A study nurse will administer  a single oral dose of oxfendazole  to the subject. Escalating dose 
levels of 3, 7.5 and 15  mg/kg will be  evaluated sequentially.  
• Subjects will remain fasting (water is permitted)  for two hours after the administration of 
drug.  
• Lunch and dinner will be provided. Subjects will be allowed to eat snacks but will be 
asked to avoid drinking grapefruit juice and excessive (>2 cups) coffee.   
• 10 mL of blood for oxfendazole  level will be drawn predose and at 30 minutes, 1, 2, 3, 4, 
6, 9, and 12 hours (all times have a window of +/ - [ADDRESS_685330] a window of + /- [ADDRESS_685331] time of 
blood draw).  
• Obtain EKG 2 hr after study drug administration (+/ - 20 minutes)  
• Asses s AEs and SAEs throughout the day and prior to discharge from the CRU.  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Counseling on avoidance of pregnancy . 
• Ask subject to remain fasting (water is permitted)  for 8 hours prior to returning to the 
clinic in the morning.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
25 7.3 Follow -up – GROUPS 1 , 2 and 3 
Clinic Visit 2 , Day 2    
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food 
intake).  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• Draw 10 mL of blood for oxfendazole level prior to study drug administration  -
approximately 24 ho urs after dosing on day 1 (+/ - 4 hours)  
 
Administration of Study Medication  
A study nurse will administer  a single oral dose of oxfendazole to the subject. Escalating dose 
levels of 3, 7.5 and 15 mg/kg will be evaluated sequentially.  
• Subjects will remain fasting (water is permitted)  for two hours after the administration of 
drug.  
• Obtain 10 mL of blood 2 hr after study drug administration (+/ - 20 minutes) for 
oxfendazole level . 
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Ask subject to remain fasting (water is permitted)  for 8 hours prior to returning to the 
clinic in the morning.  
 
Clinic Visit 03 , Day 3  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food 
intake).  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and  SAEs  
• Draw 10 mL of blood for oxfendazole levels prior to study drug administration -
approximately 24 hours after dosing on day 2 (+/- 2 hours)  
• Collect 15 mL of blood for safety panels (hemoglobin, white blood cell count, including 
neutrophil count, plate let count, INR, partial thromboplastin time, Na, K, Cl, CO 2, blood 
urea nitrogen, creatinine, ALT, AST, and total bilirubin ).  
• Collect urine for dipstick  testing  for protein and glucose .  
 
Administration of Study Medication  
A study nurse will administer  a single oral dose of oxfendazole to the subject. Escalating dose 
levels of 3, 7.5 and 15 mg/kg will be evaluated sequentially.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
26 • Subjects will remain fasting (water is permitted)  for two hou rs after the administration of 
drug.  
• Obtain EKG 2 hr after study drug administration (+/ - 20 minutes)  
• Obtain 10 mL of blood  2 hr after study drug administration (+/ - 20 minutes) for 
oxfendazole levels  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Ask subject to remain fasting (water is permitted)  for 8 hours prior to returning to the 
clinic in the morning.  
Clinic Visit 04 , Day 4  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food 
intake).  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• Collect 10 mL of blood for oxfendazole level approximately 24 hours following dos ing on 
day 3  (+/- 2 hours) . 
 
Administration of Study Medication  
A study nurse will administer  a single oral dose of oxfendazole to the subject. Escalating dose 
levels of 3, 7.5 and 15 mg/kg will be evaluated sequentially.  
• Subjects will remain fasting (water is permitted)  for two hours after the administration of 
drug.  
• Obtain 10 mL of blood  2 hr after study drug administration (+/ - 20 minutes) for 
oxfendazole levels  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Ask subject to remain fasting (water is permitted)  for 8 hours prior to returning to the 
clinic in the morning.  
 
Clinic Visit 05 , Day 5 : 
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food 
intake).  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• A heparin lock will be inserted,  blood will be drawn (10 mL) for oxfendazole levels prior 
to study drug administration -approximately 24 hours after dosing on day 4 (+/- 2 hours)  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
27 • Collect 15 mL of blood for safety panels (hemoglobin , white blood cell count, including 
neutrophil count, platelet count, INR, partial thromboplastin time, Na, K, Cl, CO 2, blood 
urea nitrogen, creatinine, ALT, AST, and total bilirubin ). 
• Collect urine for dipstick  testing  for protein and glucose .  
 
 
Administ ration of Study Medication  
A study nurse will administer  a single oral dose of oxfendazole to the subject. Escalating dose 
levels of 3, 7.5 and 15 mg/kg will be evaluated sequentially.  
• Subjects will remain fasting (water is permitted)  for two hours after the administration of 
drug.  
• Lunch and dinner will be provided. Subjects will be allowed to eat snacks but will be 
asked to avoid drinking grapefruit juice and excessive (>2 cups) coffee.   
• 10 mL of blood for oxfendazole  level will be drawn predose and at 30 minutes, 1, 2, 3, 4, 
6, 9, and 12 hours (all times have a window of +/ - [ADDRESS_685332] a window of +/ - [ADDRESS_685333] time of 
blood draw).  
• Obtain EKG 2 hr afte r study drug administration (+/ - 20 minutes)  
• Assess AEs and SAEs  throughout the day and prior to discharge from the CRU.  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Counseling on avoidance of pregnan cy. 
• Ask subject to remain fasting (water is permitted)  for 8 hours prior to returning to the 
clinic in the morning.  
Clinic Visit 06, Day 6  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam will be perf ormed if indicated  
• Review concomitant medications  
• Review for AEs and SAEs .  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Collect 10 mL of blood for oxfendazole level  approximately 24 hours after dosing on day 
5 (+6 hours)  
Clinic Visit 0 7, Day 8 (+/- 1 day)  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs .  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Collect 10 mL of blood for oxfendazole level  
• Collect 15 mL of blood for safety panels (hemoglobin, white blood cell count, including 
neutrophil  count, platelet count, INR, partial thromboplastin time, Na, K, Cl, CO 2, blood 
urea nitrogen, creatinine, ALT, AST, and total bilirubin ).  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
28 • Collect urine for dipstick  testing  for protein and glucose . 
• An EKG will be performed  and will be reviewed by a cardiologist.  
7.4 Final Study Visit  08 – Day 10 (+/ - 2 days)  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs .  
• Collect 10 mL of blood for oxfendazole level. 
• Collect 15 mL of blood for safety panels (hemoglobin, white blood cell count, including 
neutrophil count, platelet count, INR, partial thromboplastin time, Na, K, Cl, CO 2, blood  
urea nitrogen, creatinine, ALT, AST, and total bilirubin ).  
• Collect urine for dipstick  testing  for protein and glucose . 
• Counseling on avoidance of pregnancy . 
7.5 Enrollment/Baseline - GROUP 4 
Clinic Visit 01, Day 1   
Eligible subjects will be asked to return to the Clinical Research Unit (CRU) having fasted for 8 
or more hours.  
 
General  
• Review inclusion/exclusion criteria (including assessment of time of last oral food intake  
and laboratory results obtained at the screening visit, Day 00 ). 
• Randomize to either fasting (water is permitted)  or fed using the IDES system  
• Review concomitant medications including confirmation of a bsence of medications in the 
past 48 hours.  
• A brief in terim medical history will be taken.  
• A routine physical examination that assesses general appearance and the following 
areas/systems, including skin, lymph nodes, HEENT, neck, respi[INVESTIGATOR_696], cardiovascular, 
pulmonary, abdomen, extremities, musculoskeletal, a nd neurological will be performed 
by a clinician licensed to make diagnoses.  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Perform a urine pregnancy test for females of childbearing potential.  
• A heparin lock will be inserted, blood will be drawn (10 mL) for baseline PK (prior to 
product administration), and (15 mL) for safety labs (hemoglobin, white blood cell count, 
including neutrophil count, platelet count, INR, partial thromboplastin time, creatinine, 
Na, K, CL, CO 2, blood urea nitrogen, ALT, AST, and total bilirubin ). 
• Collect urine for dipstick  testing  for protein and glucose . 
• For subjects randomized to receive a high fat meal during the first dose, provide high fat 
breakfast.  For subjects randomized to rece ive the first dose following an [ADDRESS_685334], 
proceed to next steps without providing food.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
29    
Administration of Study Medication  
A study nurse will administer  a single 3 mg/kg oral dose of oxfendazole to the subject.   
• Fasting (water is permitted)  subjects will remain fasting (water is permitted)  for two hours 
after the administration of drug.  
• Fed subjects will receive a high fat breakfast . Approximately 30 minutes (+/ - 15 minut es) 
following completion of the meal, the study nurse will administer a single 3 mg/kg oral 
dose of oxfendazole.    
• Lunch and dinner will be provided. Subjects will be allowed to eat snacks but will be 
asked to avoid drinking grapefruit juice and excessive  (>2 cups) coffee.   
• 10 mL of blood for oxfendazole level will be drawn at 30 minutes, 1, 2, 3, 4, 6, 9, and 12 
hours (all times have a window of +/ - [ADDRESS_685335] a window of +/ - [ADDRESS_685336] time of blood 
draw).  
• Perform EKG approximately 2 hours following study drug (+/ - 20 minutes)  
• Assess AEs and SAEs  throughout the day and prior to discharge from the CRU.  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Counseling on avoidance of pregnancy . 
7.6 Follow -up – GROUP 4 
Clinic Visit 02 , Day 2   
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• Draw 10 mL of blood for oxfendazole level -approximately 24 hours after dosing on day 
1 (+/- 4 hours)  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
 
Clinic Visit 03 , Day 4  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• Collect 15 mL of blood for s afety panels (hemoglobin, white blood cell count, including 
neutrophil and eosinophil counts, platelet count, INR, partial thromboplastin time, Na, K, 
Cl, CO 2, blood urea nitrogen, creatinine, ALT, AST,  and total bilirubin ). 
• Collect urine for dipstick  testing for protein and glucose . 
• Remind subjects to remain fasting (water is permitted)  for 8 or more hours prior to stud y 
visit 0 4. 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
30 • Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
 
Clinic Visit 04 , Day 8 (+/ - 1 day)  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Review inclusion/exclusion criteria (including assessment of time of last oral food 
intake).  
• Perform a urine pregnancy test for females of childbearing potential.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• A heparin lock will be inserted, blood will be drawn (10 mL) for baselin e PK (prior to 
product administration)  
 
 
Administration of Study Medication  
A study nurse will administer  a single 3 mg/kg oral dose of oxfendazole to the subject.  
• For subjects who fasted during the first day of study drug administration, provide high fa t 
breakfast prior to study drug administration .  Approximately 30 minutes (+/ - 15 minutes)  
following completion of the meal, the study nurse will administer a single 3 mg/kg oral 
dose of oxfendazole.    
• For s ubjects  who received a meal prior to the first day of study drug administration,  
subjects should fast for 8 hours prior to receipt of study drug and remain fasting (water is 
permitted)  for two hours after the administration of drug.  
• Lunch and dinner will be prov ided. Subjects will be allowed to eat snacks but will be 
asked to avoid drinking grapefruit juice and excessive (>2 cups) coffee.   
• 10 mL of blood for oxfendazole level will be drawn at 30 minutes, 1, 2, 3, 4, 6, 9, and 12 
hours (all times have a window of  +/- [ADDRESS_685337] a window of +/ - [ADDRESS_685338] time of blood 
draw).  
• Perform EKG approximately 2 hours following study drug (+/ - 20 minutes)  
• Assess AEs and SAEs  throughout the day and prior to discharge from the CRU.  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
• Counseling on avoidance of pregnancy . 
 
Clinic Visit 0 5, Day 9 : (or 1 day following second dose)  
• Vital signs incl uding oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
31 • Draw 10 mL of blood for oxfendazole level -approximately 24 hours after dosing on day 
8 (+/- 2 hours)  
• Counsel on need to avoid alcohol, drugs, tobacco and medications throughout the study.  
7.7 Final Study Visit 06 Day 14  (+/- 2 days ) - GROUP 4 
• Vital signs incl uding oral temperature, blood pressure, and pulse will be obtained.  
• A targeted physical exam may be performed, if indicated.  
• Review concomitant medications  
• Review for AEs and SAEs  
• Draw 10 mL of blood for oxfendazole level  
• Collect 15 mL of blood for safety  panels (hemoglobin, white blood cell count, including 
neutrophil count, platelet count, INR, partial thromboplastin time, Na, K, Cl, CO 2, blood 
urea nitrogen, creatinine, ALT, AST, and total bilirubin ).  
• Collect urine for dipstick  testing  for protein and glucose . 
• Counseling on avoidance of pregnancy . 
7.[ADDRESS_685339] withdraws from the study early, the following procedures should be performed at the 
early termination visit.  
• Review current health status (interim medical history) and note a ny changes since the 
last visit  
• Review concomitant medications  
• Vital signs including oral temperature, blood pressure, and pulse will be obtained.  
• Blood and urine will be collec ted for safety laboratory tests   
• Blood  will be obtained for PK studies  
• A targeted physical examination may be performed, if indicated.  
• Information regarding AEs and SAEs will be solicited.  Any ongoing AEs or SAEs will be 
followed to resolution or until a stable chronic condition has been established.  
Follow -up assessments will be completed according to the protocol schedule, if possible.  
7.9 Unscheduled Visit  
Unscheduled visits may occur at any time during the study. Unscheduled visits may occur after 
the sch eduled final study visit (Day 10 o r 14, depending on Study Group ) if necessary to follow 
any AE occurring during the study period to resolution or stability. The procedures below are to 
be performed at any unscheduled visit. See the M anual of Procedures (M OP) for instructions on 
documentat ion and data reporting.  
• Interim medical history will be reviewed.  
• Review concomitant medications . 
• Vital signs (P, BP, oral T), if clinically indicated will be obtained . 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
32 • A targeted physical exam, if indicated based on symptoms will be performed . 
• Adverse eve nts and serious adverse events  will be reviewed.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
33 8 STUDY PROCEDURES/EVA LUATIONS  
8.1 Clinical Evaluations  
Medical History:  Will be obtained by [CONTACT_468460]. Subjects will be queried 
regarding a history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, 
cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, nervo us system, 
blood, lymph glands, endocrine system, musculoskeletal system, skin, and genital/reproductive 
tract. A history of any allergies, cancer, immunodeficiency, psychiatric illness, substance abuse, 
and autoimmune disease will be solicited.  
Interim Medical History:  Will be obtained by [CONTACT_468460]. Subjects will be queried 
regarding new signs or symptoms that have occurred  since the screening medical history was 
obtained.  
Concomitant Medications : All current medications and medications t aken in the 30 days 
before the screening visit  (prescription and over -the-counter drugs) will be documented, as well 
as vitamins and supplements, and alternative/complementary medications  through the last 
study visit.  Assessment of eligibility also will include a review of prohibited medications (per the 
exclusion criteria).  
Physical Examination:  This examination will be conducted at Screening and Visit 1 and will 
assess general appearance including height and weight (at Screening only), vital signs (blood 
pressure, temperature, pulse), and the following areas/symptoms: skin, lymph nodes, head, 
eyes, ears, nose, throat, respi[INVESTIGATOR_696], cardiovascular, abdomen, extremities, musculoskeletal, 
and neurological.  
Vital Signs a nd Targeted Physical Examination:  Vital signs will be collected at each 
scheduled study visit  and at the Early Termination Visit . Vital signs will be collected if indicated 
at the unscheduled visit.  A targeted physical examination may be conducted at any study visit 
based on interim medical history.  
Adverse Events Assessments: Subjects will be asked if they have any new symptoms since 
the prior visit.  Please see section 9.2.1 and 9.2.2.  
8.2 Laboratory Evaluations  
8.2.1  Clinical Laboratory Evaluations  
Clinical laboratory evaluations will be performed by [CONTACT_527869].  
Specific tests to be performed are described below:  
Hematology  includes: hemoglobin, WBC count, neutrophil count, platelets  
  
Coagulation includes: INR and partial thromboplastin time  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
34 Clinical chemistry  includes: Na, K, Cl, CO 2, blood urea nitrogen, creatinine, ALT, AST, 
total bilirubin  
Serology: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus 
(HCV) antibody  
Urinalysis  will be performed by [CONTACT_527870].  Confirmatory testing may be sent to the University of Iowa Clinical 
Pathology Laboratory for reflectance spectrophotometry analysis. Note: Urinalysis may 
be deferred if a participant is menstruating, but should be performed as soon as 
possible.  
Urine Pregnancy Test: will be performed  at screening and Day 1 in females of child 
bearing potentia l for all groups.  
EKG: will be performed in the research clinic by [CONTACT_527871]. EKG tracings will be interpreted by a board certified cardiologist.   
One or more of the laboratory parameters may be repeated at any time during the study as 
determined by [CONTACT_978], if indicated by [CONTACT_1149]. A clinically significant abnormal value should be 
repeated within [ADDRESS_685340]. Gu ohua An lab at the University of 
Iowa .  
Blood samples for PK analysis will be collected in tubes containing sodium heparin as the 
anticoagulant at baseline. The blood samples (10 mL) will be placed on ice after draw, and 
centrifuged within 1 hour at 4 -8°C at approximately 3000 rpm for 15 min. The plasma will then 
be collected and stored frozen at –80°C until  analyzed.  Plasma samples will be shipped to the 
analytical lab  frozen . Validated methods will be used to assay the oxfendazole concentration in 
each sample.  
8.2.3  Specimen Preparation, Handling, Storage, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Instructions for Specimen Preparation, Handling, Storage , and 
 Shippi[INVESTIGATOR_527851], hand ling, storage, and shippi[INVESTIGATOR_527852].  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
35 9 ASSESSMENT OF SAFETY  
9.1 Specification of Safety Parameters  
Safety outcome measures are defined in Section 3.2 and include the rate of SAEs and non -
serious severe AEs.  
9.2 Methods and Timing for Assessing, Recording, and Analyzing 
Safety Parameters  
9.2.1  Adverse Events  
 
Adverse Event:    
ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product regardless of its causal rel ationship to the study 
treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of medicinal 
(investigational) product.  The occurrence of an A E may come to the attention of study 
personnel during study visits and interviews of a study recipi[INVESTIGATOR_12189], or 
upon review by a study monitor.  
All AEs including local and systemic reactions not meeting the criteria for “serious adv erse 
events” should be captured on the appropriate CRF.  Information to be collected includes event 
description, time of onset, clinician’s  assessment of severity, relationship to study product 
(assessed only by [CONTACT_527872] e a diagnosis, which would 
include MD, PA, Nurse Practitioner, DO, or DDS), and time of resolution/stabilization of the 
event.  All AEs occurring while on study must be documented appropriately regardless of 
relationship.  All AEs will be followed to adequ ate resolution.  
Any medical condition that is present at the time that the patient is screened should be 
considered as baseline and not reported as an AE.  However, if it deteriorates at any time 
during the study, it should be recorded as an AE.  
All AEs m ust be graded for severity and relationship to study product.  
FDA defines an AE as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
36 Severity of Event:   All AEs will be assessed by [CONTACT_527873] a protocol defined grading 
system.  For events not included in the protocol defined grading system, than the following 
guidelines will be used to quantify intensity.  
Grade 1:  Mild:  events require minimal or no treatment and do not interfere  with the patient’s 
daily activities.  
Grade 2:  Moderate :  events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning.  
Grade 3:  Severe :  events interrupt a patient’s  usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity t o be performed.  Adverse events characterized as 
intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
Relationship to Study Products:   The clinician’s assessment of an AE's relationship to test 
article (vaccine or study drug) is part o f the documentation process, but it is not a factor in 
determining what is or is not reported in the study.  If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported.  All AEs must have their relationship to 
study p roduct assessed using the terms:  related or not related.  In a clinical trial, the study 
product must always be suspect.  To help assess, the following guidelines are used.  
• Related  – There is a reasonable possibility that the study product caused the adve rse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the eve nt. 
9.2.2  Serious Adverse Events  
Serious Adverse Event (SAE) :  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator or sponsor, it results in any of the following outcomes:  
• Death,  
•  a life -threatening adverse event *,  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
37 • a congenital anomaly/birth defect.   
• Important medical events that  may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical 
judgment they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of  the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the d evelopment of drug dependency or drug abuse.  
* Life-threatening adverse event. An adverse event is considered “life -threatening” if, in the view 
of either the investigator or sponsor, its occurrence places the patient or subject at immediate 
risk of death.   It does not include an adverse event, had it occurred in a more severe form, might 
have caused death.  
All SAEs will be:  
• recorded on the appropriate SAE CRF  
• followed through resolution by a study clinician  
• reviewed and evaluated by a study clinician  
9.2.[ADDRESS_685341] Values or Abnormal Clinical Findings  
The site principal investigator [INVESTIGATOR_29353] -investigator is responsible for reporting all 
AE/SAEs that are observed or reported during the study, rega rdless of the relationship to study 
product.  All clinically significant EKG abnormalities will be reported as an AE.   
AE/SAEs, abnormal clinical laboratory test values  or clinically significant EKG changes , or 
abnormal clinical findings will be documente d, reported, and followed until the event has 
resolved or has stab ilized.  
If baseline clinical labs fall within Grade 1 parameters, then an AE is reported only if the value 
changes such that it falls into Grade 2 or higher at subsequent visits. For labora tory results that 
are abnormal according to the local laboratory reference range, but not considered a Grade 1 
abnormality, these will not be considered AEs and will thus not be graded, but will be followed -
up clinically at the discreti on of the study site  physician.  
  
9.3 Reporting Procedures  
AEs will be documented from the time of receipt of study drug on Day 1 (Visit 02) through the 
final study visit ( approximately [ADDRESS_685342] ). 
SAEs will be documented from the time of receipt of study drug on Day 1 (Visit 02) through the 
final study visit . 
DMID [ADDRESS_685343] be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
 
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_685344]. Suite 650  
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE FAX Phone Number: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE Email Ad dress: [EMAIL_1393]  
 
Other supporting documentation of the event may be requested by [CONTACT_140159].  
 
The DMI D medical monitor and clinical protocol manager will be notified of the SAE by [CONTACT_413656].  The DMID medical monitor will review and assess the SAE 
for regulatory reporting and potential impact on study subject safety and protocol con duct.  
 
At any time after completion of the study, if the investigator becomes aware of an SAE that is 
suspected to be related to study product, the investigator will report the event to the DMID 
Pharmacovigilance Group.  
9.3.[ADDRESS_685345] a causal relationship between 
the drug and the adverse event.  DMID will notify FDA and all participating investigators (i.e., all 
investigators to whom the sponsor is providing drug under its INDs or under any investigator’s  
IND) in an IND safety report of potential serious risks from clinical trials or any other source, as 
soon as possible, but in no case later than 15 calendar days after the sponsor determines that 
the information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify 
FDA of any unexpected fatal or life -threatening suspected adverse reaction as soon as possible 
but in no case later than 7 calendar days after the sponsor’s initial receipt of the information. 
Relevant follow up infor mation to an IND safety report will be submitted as soon as the 
information is available.  Upon request from FDA, DMID will submit to FDA any additional data 
DMID [ADDRESS_685346].  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format.  
9.3.3  Regulatory Reporting for Studies Not Conducted Under 
DMID -Sponsored IND  
N/A. 
9.3.4  Other Adverse Events (if applicable)  
N/A 
9.3.[ADDRESS_685347]’s permission.  
9.[ADDRESS_685348] receipt of study drug Day 1 (Visit 02) 
through the last subject’s study visit.  
AEs and SAEs will be followed until resolution even if this extends beyond the study -reporting 
period.  Resolution of an AE/SAE is defined as the return to pretreatment status or stabilization 
of the condition with the expectation that it will remain chronic.  
If the site principal investigator [INVESTIGATOR_29353]-investigator  becomes aware of a sign or 
symptom and the site principal investigator [INVESTIGATOR_122747]-investigator  decides to bring the 
subject in for an evaluation to determine etiology, then the site principal investigator [INVESTIGATOR_168702]-investigator , at their own discretion, can determine what further testing is 
appropriate.  
Follow -up procedure s, evaluations, and outcomes will be recorded on the appropriate data 
collection form.  
9.[ADDRESS_685349] Halting Rules  
For each of the multiple dose ascending groups  (Groups 1 -3), one sentinel subject  will be dosed 
and monitored for [ADDRESS_685350] s’ halting criteria are met:  
•         any study drug related SAE  
•         any study drug related grade 3 AE or laboratory abnormality    
•         any two Grade 2 AE or laboratory abnormalities of the same laboratory parameter  
that are study drug related  
then the remaining subjects in each group may be enrolled .  
9.5.2  Dose Escalation Halting Criteria  
Prior to dose escalation to the next cohort, the Statistical and Data Coordinating Center (SDCC) 
will notify the study PIs, DMID medical monitor (MM), and DMID Independent Safety Monitor 
(ISM) whether the below dose escalation criterion were met.   Following enrollment and 10 days 
of safety follow up of the eight subjects in the dose group.  
Dose escalation will not proceed if any of the following dose escalation criteria occur:  
•         any study drug related SAE  
•         any study drug related grade 3 AE or laboratory abnormality    
•         any two Grade 2 AE or laboratory abnormalities  of the same laboratory parameter  
In addition to these criteria, dose escalation may also stop for other reasons per the advice of 
the SMC, ISM, or DMID Medical Monitor for further evaluation, discussion, and 
recommendations from the SMC.  
If the above do se escalation halting criteria are NOT met, the dose escalation may proceed with 
agreement of DMID.    
9.5.3  Study Halting Rules  
Enrollment , dosing  and study procedures will be halted for SMC review/recommendation if any 
of the following are reported:  
• Any death occurring after administration of study drug through the subject’s last study 
visit that was not the result of trauma or accident, regardless of relatedness to study 
product.  
• Any subject experiences laryngospasm, bronchospasm, or anaphylaxis within one day 
after administration of study product.  
• Any subject experiences a study drug -related Stevens Johnson Syndrome.  
• Two or more subjects experience generalized urticaria within three days after 
administration of study product.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
41 • Any subject experiences a st udy drug -related SAE from the time of receipt of study drug 
through the subject’s last study visit.  
• Two or more  subject s develop new QTc prolongation on EKG that are deemed clinically 
significant by a reviewing cardiologist.  
• Two or more  subject s develop g rade [ADDRESS_685351] receipt of study drug, the study will not 
continue with the remaining enrollments without a review by [CONTACT_527874].  
DMID retains the authority to suspend additional enrollment and study 
interventions/administration of study product during the entire study, as applicable.  
9.5.4  Individual Halting R ules 
• Subject experiences laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_685352].  
• Subject experiences a study drug -related Stevens Johnson Syndrome.  
• Subject experience generalized urticaria within [ADDRESS_685353]. 
• Subject experiences a study drug -related SAE from the time of receipt of study drug 
through the subject’s last study visit.  
• Subject develops new  QTc prolongation on  EKG that are deemed clinically significant by 
a reviewing cardiologist.  
•  Subject deve lops any grade 3 laboratory abnormalities deemed related to the study 
drug.  
• Subject develops any grade 3 AE deemed related to the study drug.  
 
9.6 Safety Oversight (ISM plus SMC) 
Safety oversight will be under the di rection of an SMC .  The SMC will have a form al meeting 
after the third study group has completed the day [ADDRESS_685354] study group has completed the day 10 study visit.  
This meeting will be scheduled expeditiously ..  If halting rules are identified , more frequent 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
42 meetings may be held.  The SMC  will operate under the rules of a DMID -approved charter that 
will be written at the organizational meeting of the SMC .  At this time, each data element that 
the SMC  needs to asses s will be clearly defined.  The SMC  will advise DMID of its findings.  
 
9.6.1  Independent  Safety Monitor (ISM)  
The ISM is a physician with relevant expertise whose primary responsibility is to provide 
independent safety monitoring in a timely fashion. The ISM wil l review SAEs and other A Es as 
needed and provide an independent assessment to DMID. The University of Iowa will have an 
ISM with experience in infectious diseases or internal medicine.  
9.6.2  Safety Monitoring Committee (SMC)  
The SMC is an independent group of e xperts that advises DMID and the study investigators for 
many Phase [ADDRESS_685355] access to unblinded data dur ing its closed session.    
  
The SMC will review and discuss safety data at the following milestones:  
 
• The SMC will review available safety data for Groups [ADDRESS_685356] study group 
has completed the day 10 study visit.  Ad hoc review: may be in response to an 
anticipated safety issue such as a dose escalation or study halting rule being met.  
 
 
• Final review meeting: [ADDRESS_685357] protection, study procedures, 
laboratory procedures, study intervention administration, and data collection processes are of 
high qualit y and meet sponsor, ICH/GCP guidelines and applicable regulatory requirements, 
and that the study is conducted in accordance with the protocol and sponsor’s standard 
operating procedures. The DMID or its designee will conduct site -monitoring visits as spec ified 
in the monitoring plan.  
Monitoring visits will include, but are not limited to, review of regulatory files, accountability 
records, CRFs, informed consent forms, medical and laboratory reports, and protocol 
compliance. Study monitors will meet with i nvestigators to discuss any problems and actions to 
be taken and document visit findings and discussions.  
DMID [ADDRESS_685358] of food on the kinetics of 
oxfendazol e. 
Primary endpoints : 
1. The rate of adverse events (A Es) related to oxfendazole within 10 days of receipt of 
oxfendazole given for 5 sequential, daily oral doses of either 3, 7.5 or 15 mg/kg  
 
2. The rate of adverse events (A Es) related to oxfendazole within [ADDRESS_685359] or following a 
high fat meal.  
 
 
Secondary endpoints:  
1. Plasma Cmax, Tmax, AUC, T 1/2 of oxfendazole at specified time points following each 
dose of a 5 day daily regimen of either 3, 7.5 or 15 mg/kg  
 
2. Plasma Cm ax, Tmax, AUC, T 1/[ADDRESS_685360] of food on the kinetics  of oxfendazole , equivalence between the 
fasting (water is permitt ed) and fed conditions will be tested using 90% confidence intervals and 
80-125% equivalence limits for AUC 0-, AUC 0-24, and C max in accordance with FDA guidance . 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
45 11.2 Sample Size Considerations  
The sample sizes were selected to obtain preliminary safety information on a small cohort of 
subjects before proceeding to larger trials.  In this Phase 1  study, we are concerned with rates  
of adverse events, which theoretically could occur due to oxfendazole  treatment .  The dosing 
regimens  with respective sample sizes are described in Table 4 below:  
Table 4 .  Sample sizes for each dose regimen  
Cohort  Dose Regimen  Sample size  
1 3 mg/kg daily for 5 days  8 
2 7.5 mg/kg daily for 5 days  8 
3 15 mg/kg daily for 5 days  8 
4 Single dose of 3 mg/kg after fasting (water is permitted)  with 
cross -over to single dose of 3 mg/kg after high -fat meal.  [ADDRESS_685361] of 
food on the kinetics  of oxfendazole , the power is 80% when the coefficient of variation is less 
than 0.175 and 64% when the coefficient of variation is 0.2.  
11.3 Planned Interim Analyses (if applica ble) 
No interim analyses are planned.  
11.3.[ADDRESS_685362]  completed the day 10 
study visit.  This meeting will be scheduled expeditiously, but this SMC review is not required 
prior to enro llment into study group 4.  This report  will summarize adverse events as described 
in section 11.4.3  below.   Additional safety review may occur if halting rules are met.   
11.4 Final Analysis Plan  
The final analysis will be performed and clinical study report c ompleted when all primary and 
secondary endpoint data are available.  This study, like other Phase 1 studies, is exploratory 
rather than confirmatory; its purpose is to estimate adverse event rates and characterize 
pharmacokinetic profiles than to test for mal statistical hypotheses.  Estimates will be presented 
with their 95% confidence intervals.  Results will be presented in tabular format, as well as 
graphically when appropriate.   
11.4.[ADDRESS_685363] one evaluable PK concentration will be 
eligible for the PK analysis populati on. 
11.4.2  Analysis of Demographics  
Demographic characteristics (age, gender, race, ethnicity) of each cohort will be summarized 
numerically.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
47 11.4.3  Analysis of Safety  
Adverse experiences (spontaneous reports) will be coded into MedDRA ® preferred terms. The 
number of subjects experiencing unsolicited adverse events and the number of spontaneous 
events, classified using MedDRA® System Organ Classes and Preferred Terms, reported 
throughout the study after treatment administration  will be t abulated by [CONTACT_9084] .  The severity  and 
relationship to study product of the unsolicited adverse events will also be assessed.  Serious 
adverse events will be described.  A complete listing of adverse experiences for each subject 
will provide details includi ng severity, relationship to treatment , onset, duration, and outcome. 
Solicited clinical laboratory results and vital signs will be graded and summarized by [CONTACT_527875].    
11.4.4  Pharmacokinetic Analysis  
PK parameters for oxfendazole will be calculated u sing non -compartmental analysis. 
Parameters will be summarized separately by [CONTACT_527876].  
Maximum concentration ( Cmax), time of maximum concentration ( Tmax), and the pre -dose trough 
concentrations (C trough) will be directly estimated  from the observed concentration -time curve . 
Area under the curve (AUC) will be calculated using the linear up -log down trapezoidal method.  
λz will be calculated as the negative of the slope of the terminal log -linear segment of the 
plasma concentration -time curve. The range of data to be used for each subject and treatment 
will be determined by [CONTACT_283674] a semi -logarithmic plot of concentration vs. time, but 
will include at least three plasma concentration -time points  for λ z to be estimable . Half-life (t ½) 
will be calculated as ln(2)/ λz.  
In Groups 1 -3, AUC 0-τ will be calculated as AUC to the end of the 24 -hour dosing interval.  Oral 
clearance at steady state  will be calculated using AUC 0-τ,ss after the Day 5 (expected steady 
state) dose as  
ssssAUCDoseF CL
, 0/
−=
. 
The observed accumulation ratio (AR) following multiple dosing will be estimated using the ratio 
of AUC 0-τ following multiple and single dosing. When λz is estimable, AR will also be estimated 
using λz calculated following multiple dosing:  
𝐴𝑅=1
1−𝑒−λ𝑍𝜏 
 
The relationship between exposure ( Cmax and AUC ) and dose, i.e., dose proportionality, will be 
examined using ANOVA or the power model  
bDose a P =
 
where P represents the parameter and a and b are constants.  A value of b of approximately 1 
indicates linear PK.   
 
Group 4 parameters will be summarized by [CONTACT_3004] ( fasting (water is permitted)  or fed). In 
group 4, 90% confidence intervals for ratios of key exposure parameters will be estima ted using 
appropriate analysis of variance (ANOVA) models on the log -transformed parameters.  Key 
exposure parameters will be Cmax, AUC to the time of the last quantifiable concentration 
(AUC 0-t), and, when λz is estimable, AUC extrapolate d to infinity ( AUC 0-∞). 
DMID [ADDRESS_685364] plasma concentrations, actual blood sampling times, PK 
parameters, and graphs of concentration vs. time will be prepared by [CONTACT_19313]. Param eter 
estimation using noncompartmental analysis  will be done using appropriate computer software , 
such as Phoenix WinNonlin , as determined by [CONTACT_456].  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
49 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS  
The site will maintain appropriate medical and research records for this trial, in compliance with 
ICH E6, Section 4.[ADDRESS_685365] access to records.  As part of participating in 
a DMID -sponsored, DMID -affiliated, or manufacturer -sponsored study, each site will permit 
authorized representatives of the sponsor(s), DMID, and regulatory agencies to examine (and 
when required by [CONTACT_1289], to copy) clin ical records for the purposes of quality assurance 
reviews, audits, and evaluation of the study safety and progress.  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for  the reconstruction and evaluation of the trial.  Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects’ memory aid or evaluation 
checklist s, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical 
trial. It is acceptable to use CRFs as source documents.  If this is the case, it should be stated in 
this section what data will be collected on C RFs and what data will be collected from other 
sources.   
DMID [ADDRESS_685366] access to all trial -
related sites, source data/documents, and reports for the purpose of monitoring and auditing by 
[CONTACT_456], and inspection by [CONTACT_19566] l and regulatory authorities. The PI [INVESTIGATOR_527853].  
DMID -designated clinical monitors will verify that the clinical trial is conducted and data are 
generated, d ocumented (recorded), and reported in compliance with the protocol, ICH/GCP 
guidelines, and the applicable regulatory requirements. Clinical monitoring reports will be 
submitted to DMID.  
The SDCC will implement quality control procedures beginning with the  data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
51 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.[ADDRESS_685367]  
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commission for the Protectio n of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the 
ICH E6; 62 Federal Regulations [ZIP_CODE] (1997).   
14.[ADDRESS_685368]  
 
Prior to enrollment of subjects into this trial, the approved pr otocol and the informed consent 
form will be reviewed and approved by [CONTACT_19821]. The responsible official for the IRB 
will sign the IRB letter of approval of the protocol prior to the start of this trial and a copy will be 
provided to DMID. Notif ication of the IRB ’s composition, or the IRB’s Federal Wide Assurance 
number, will be provided to DMID. Should amendments to the protocol be required, the 
amendments will be written by [CONTACT_527877]. 
14.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continuing throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of t his therapy will be provided to the subjects and their families.  
Consent forms describing in detail the study interventions/products, study procedures, and risks 
are given to the subject and written documentation of informed consent is required prior to 
starting intervention/administering study product.  Consent forms will be IRB -approved and the 
subject will be asked to read and review the document. Upon reviewing the document, the 
investigator will explain the research study to the subject and answer any  questions that may 
arise.  The subjects will sign the informed consent document prior to any procedures being done 
specifically for the study.  The subjects should have the opportunity to discuss the study with 
their surrogates or think about it prior to agreeing to participate.  The subjects may withdraw 
consent at any time throughout the course of the trial.  A copy of the informed consent 
document will be given to the subjects for their records.  The rights and welfare of the subjects 
will be protected by [CONTACT_132441].  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
52 14.3.1  Informed Consent/Assent Process (in Case of a Minor)  
Not applicable  
14.4 Exclusion of Women, Minorities, and Children (Spe cial 
Populations)  
This study will be inclusive of all healthy adults who meet the inclusion/exclusion criteria, 
regardless of religion, sex, or ethnic background. Only individuals, who are [ADDRESS_685369] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents.  This confidentiality is extended to cover t esting of biological 
samples and genetic tests in addition to the clinical information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence.  No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor.  
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required  to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study.  The 
clinical study site will permit access to such records.  
14.6 Study Discontinuation  
If the study is discontinued, enrolled subjects will continue to be followed for safety 
assessments.  
Subjects will be compensated for their participation in this study. Compensation will be in 
accordance with the local IRB’s policies and procedures and subject  to IRB approval.  
14.[ADDRESS_685370] KEEPI[INVESTIGATOR_114744], completeness, legibility, and timeliness 
of the data reported.  All source documents should be completed in a neat, legible manner to 
ensure accurate interpretation of data.  Black ink is required to ensure clarity of reproduced 
copi[INVESTIGATOR_014].  When making changes or corrections, cross out the original entry with a single line, and 
initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE CORRECTI ON FLUID 
OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and 
maintained for recording data for each subject enrolled in the study.  Data reported in the eCRF 
derived from source documents should be consistent with the source documents or the 
discrepancies should be explained  
DMID and/or it designee will provide guidance to investigators on making corrections to the 
source documents and eCRF.  
15.[ADDRESS_685371] maintain complete and accurate 
documentation for the study.  
The EMMES Corporation will serve as the Statistical an d Data Coordinating Center for this 
study and will be responsible for data management, quality review, analysis, and reporting of 
the study data.  
15.2 Data Capture Methods  
Clinical data (including A Es, concomitant medications, and reactogenicity data) and clini cal 
laboratory data will be entered into a 21 CFR Part 11 -compliant Internet Data Entry System 
(IDES) provided by [CONTACT_527878].  The data system includes password protection 
and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly from the source 
documents.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
54 15.3 Types of Data  
Data for this study will include safety, laboratory studies, EKG data and pharmacokinetic data 
for the study drug.  
15.4 Timing/Reports  
Safety data will be reviewed by [CONTACT_527879].  The SMC will 
review available safety data for Groups [ADDRESS_685372].  These documents should 
be retained for a long er period, however, if required by [CONTACT_427].  No records will be 
destroyed without the written consent of the sponsor, if applicable.  It is the responsibility of the 
sponsor to inform the investigator when these documents no longer need to be ret ained.  
15.6 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice 
(GCP), or Manual of Procedures requirements.  The noncompliance may be either on the part of 
the subject, the investigator, or the  study site staff.  As a result of deviations, corrective actions 
are to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6:  
4.[ADDRESS_685373] be promptly reported to DMID, via The 
EMMES Corporation’s IDES or via the TRI/ICON DMID -Clinical Research Operations and 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
55 Management Support (CROMS) email ( [EMAIL_10080] ), web- 
(www .dmidcroms.com ) or fax -based system (1 -[PHONE_10932]).   
Note:  Those sites participating in trials with a designated ‘central unit’ will follow the reporting 
requirements specified in their protocols and MOPs.  The ‘central unit’ will be responsible for 
submission of the protocol deviation information to TRI/ICON DMID -CROMS . 
All deviations from the protocol must be addressed in study subject source documents.  A 
completed copy of the DMID Protocol Deviation Form ( TRI/ICON DMID -CROMS  or IDES form) 
must be mai ntained in the regulatory file, as well as in the subject’s source document.  Protocol 
deviations must be sent to the local IRB/IEC per their guidelines.  The site PI/study staff is 
responsible for knowing and adhering to their IRB/IEC requirements.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
56 16 PUBLIC ATION POLICY  
 
Following completion of the study, the investigator is expected to publish the results of this 
research in a scientific journal.  The International Committee of Medical Journal Editors (ICMJE) 
member journals have adopted a trials -registration policy as a condition for publication. This 
policy requires that all clinical trials be registered in a public trials registry such as 
ClinicalTrials.gov *, which is sponsored by [CONTACT_1055].  Other biomedical 
journals are considering adopting similar policies.  It is the responsibility of DMID to register this 
trial in an acceptable registry.  Any clinical trial starting enrollment after [ADDRESS_685374] relationship 
between a medical intervention and a health outcome.  Studies designed for other purposes, 
such as to study pharmacokinetics or major toxicity (e.g., Phase I trials), would be exempt from 
this policy.  
 
 
 
 
DMID [ADDRESS_685375] Databank. Geneva, World Health Organization, 2010 
(http://www.who.int/neglected_diseases/preventive_chemotherapy/databank/en/ , accessed 
24 January 2012.  
2. Keiser J  & Utzinger J.   Efficacy of current drugs against soil -transmitted he lminth infections: 
systematic review and meta -analysis .  JAMA.  299 :1937 -1948, 2008.  
3. Review of Oxfendazole. Parasitology Today.  6( Entire Issue  4):91 -140, 1990.  
4. Marriner SE & Bogan JA.  Pharmacokinetics of oxfendazole in sheep.  Am J Vet Res. 
42:1143 -1145, 1981.  
5. Synanthic® 22.5% Label. St. Joseph, MO: Boehringer Ingelheim Vetmedica;  [December 6, 
2011]; 2010:[Available from: http://bi -vetmedica.com/products . 
6. Synanthic® 9.06% Label. St. Joseph, MO: Boehringer Ingelheim Vetmedica;  [December 6, 
2011]; 2010:[Available from: http://bi -vetmedica.com/products . 
7. Brown HD, Matzuk AR, Ilves IR, Peterson LH, Harris SA, Sarett LH, Eg erton JR, Yakstis JJ, 
Campbell WC, & Cuckler AC.   Antiparasitic Drugs IV. 2 -(4’-thiazolyl) -benzimidazole, a new 
anthelminthic.  J Am Chem Soc.  83:1764 -1765, 1961.  
8. Garcia HH, Gonzalez AE, & Gilman RH.  Diagnosis, treatment and control of Taenia solium 
cysticercosis.  Curr Opin Infect Dis.  16:411 -419, 2003.  
9. Tocco DJ, Buhs RP, Brown HD, Matzuk AR, Mertel HE, Harmon RE, & Trenner NR.  The 
metabolic phase of thiabendazole in sheep.  J Med Chem.  7:399 -405, 1964.  
10. Ali DN & Hennessy DR.  The effect of feed intak e on the rate of flow of digesta and the 
disposition and activity of oxfendazole in sheep.  Int J Parasitol.  23:477 -484, 1993.  
11. Latif LA & Surin J.  Relationships between the anthelmintic activity of eight derivatives of 
benzimidazole carbamates against Tr ichinella spi[INVESTIGATOR_527854].  Jpn J 
Med Sci Biol.  46:203 -214, 1993.  
12. Russell GJ, Gill JH, & Lacey E.  Binding of [3H]benzimidazole carbamates to mammalian 
brain tubulin and the mechanism of selective toxicity of the benzimidazole anthe lmintics.  
Biochem Pharmacol.  43:1095 -1100, 1992.  
13. Lubega GW & Prichard RK.  Interaction of benzimidazole anthelmintics with Haemonchus 
contortus tubulin: binding affinity and anthelmintic efficacy.  Exp Parasitol. 73:203 -213, 
1991.  
14. Nash TE & Neva FA.  Rec ent advances in the diagnosis and treatment of cerebral 
cysticercosis.  N Engl J Med. 311:1492 -1496, 1984.  
15. Proano JV, Madrazo I, Avelar F, Lopez -Felix B, Diaz G, & Grijalva I.  Medical treatment for 
neurocysticercosis characterized by [CONTACT_527880].  N Engl J Med. 345:879 -885. 
2001.  
16. Freedom of Information Summary, NADA 140 -854 Synanthic® -original approval. 1990 
[November 7, 2011]; Available from: 
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSum
maries/ucm049983.html . 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
58 APPEN DIX A: SCHEDULE OF E VENTS  
 
Groups 1 ,2 and 3 
 
  Follow Up Visits  
 
 
 
 
Screening  
Study Visit 00  
Baseline   
Study visit 01  
Study Visit 02  
Study Visit 03  
Study Visit 04  
Study Visit 05  
Study Visit 06  
Study Visit 07  
Study 
Completion  
 Visit 08  
Unscheduled 
Visit 
Early 
Termination 
Visit 
Study Day  D-28 
to -1 D1 D2 D3 D4 D5 D6 D8 D10   
Visit Window  N/A N/A N/A N/A N/A N/A N/A +/-1 +/-2   
Signed Consent Form  X           
Assessment of Eligibility 
Criteria  X X X X X X      
Enrollment   X          
Review of Medical History  X X        X X 
Review of Concomitant 
Medications  X X X X X X X X X X X 
Administration of Study 
Medication   X X X X X      Physical 
Examination  Complete  X X          
Symptom -
Directed    (X) (X) (X) (X) (X) (X) (X) (X) (X) 
Vital Signs  X X X X X X X X X (X) X 
Assessment of Adverse 
Events  and SAEs   X X X X X X X X X X Clinical Laboratory  Chemistry  X X  X  X  X X  X 
Hematology  X X  X  X  X X  X 
Coagulation 
Studies  X X  X  X  X X  X 
Serology  X           
Urinalysis  X X  X  X  X X  X 
Pregnancy Test  X X          Research 
Laboratory  
PK studies  
10 mL whole 
blood   X X X X X X X X  X 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
59 Groups 1 ,2 and 3 
 
  Follow Up Visits  
 
 
 
 
Screening  
Study Visit 00  
Baseline   
Study visit 01  
Study Visit 02  
Study Visit 03  
Study Visit 04  
Study Visit 05  
Study Visit 06  
Study Visit 07  
Study 
Completion  
 Visit 08  
Unscheduled 
Visit 
Early 
Termination 
Visit 
Study Day  D-28 
to -1 D1 D2 D3 D4 D5 D6 D8 D10   
Visit Window  N/A N/A N/A N/A N/A N/A N/A +/-1 +/-2   Other 
Procedures  
EKG  X X  X  X  
X    
 
(X) – As indicated/appropriate.  
Hematology  – Hemoglobin, WBC and neutrophil  count, platelet count.  
Biochemistry  – Screening : creatinine, ALT, AST, random glucose, total bilirubin . 
                      – Follow Up Visits : creatinine, sodium, potassium, chloride, carbon dioxide, blood 
urea nitrogen ALT, AST, total bilirubin.  
Coagulation Studies – INR, and partial thromboplastin time (PTT)  
Serology  – Hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency vir us (HIV)  
Urinalysis – Urine Dipstick for protein and glucose  
Research Laboratory  – Days 1 and 5 : 10 mL blood for baseline PK  (prior to drug administration), 10 
mL blood at 30 minutes, 1, 2, 3, 4, 6, 9, and 12 hours (all times have a window of +/ - [ADDRESS_685376] a window of +/ - 30 minutes ) 
Day 2 : 10 mL blood prior to study drug administration -approximately 24 hours after dosing on 
previous day  (+/- 4 hours)  and 2  hours after study drug administration (+/ - 20 minutes)  
Days 3 and 4 : 10 mL blood prior to study drug administration -approximately 24 hours after dosing 
on previous day (+/ - 2 hours)  
Day 6 : 10 mL blood -approximately 24 hours after dosing on previous day (+6hours)  
 
 
 
 
  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
60 Group 4 
 
 Follow Up Visits  
 
 
 
 
Screening  
Study Visit 0 0 
Baseline   
Study visit 01 
Study Visit 02 
Study Visit 03 
Study Visit 04 
Study Visit 05 
Study 
Completion  
Study Visit 06 
Unscheduled 
Visit 
Early 
Termination 
Visit  
Study Day  D-28 
to -1 D1 D2 D4 D8 D9 D14   
Visit Window  N/A N/A N/A N/A +/-1 N/A +/-2   
Signed Consent Form  X         
Assessment of Eligibility 
Criteria  X X   X     
Randomization/Enrollment   X        
Review of Medical History  X X      X X 
Review of Concomitant 
Medications  X X X X X X X X X 
Administration of Study 
Medication   X   X     Physical 
Examination  Complete  X X        
Symptom -
Directed    (X) (X) (X) (X) (X) (X) X 
Vital Signs  X X X X X X X (X) X 
Assessment of Adverse 
Events  and SAEs   X X X X X X X X Clinical Laboratory  Chemistry  X X  X   X  X 
Hematology  X X  X   X  X 
Coagulation 
Studies  X X  X   X  X 
Serology  X         
Urinalysis  X X  X   X (X) X 
Pregnancy Test  X X   X     Research 
Laboratory  
PK Studies  
10 mL whole 
blood   X X  X X X  X Other 
Procedures  
EKG  X X   X     
 
 
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
61 (X) – As indicated/appropriate  
Hematology  – Hemoglobin, WBC and neutrophil count, platelet count.  
Biochemistry  – Screening : creatinine, ALT, AST, random glucose, total bilirubin.  
                      – Follow Up Visits : creatinine, sodium, potassium, chloride, carbon dioxide, blood urea 
nitrogen ALT,  AST, total bilirubin.  
Coagulation Studies – INR and partial thromboplastin time (PTT)  
Serology  – Hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV)  
Urinalysis – Urine Dipstick for protein and glucose  
Research Laboratory  – Days 1 and 8: 10 mL blood for baseline PK  (prior to drug administration), 10 mL 
blood at 30 minutes, 1, 2, 3, 4, 6, 9, and 12 hours (all times have a window of +/ - [ADDRESS_685377] a window of +/ - 30 minutes ) 
Day 2  and 9 : 10 mL blood –approximately 24 hours following study drug dose  (+/- 4 hours)   
  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
62  
APPENDIX B: DMID ADULT TOXICITY TABLES  
NON -SERIOUS ADVERSE EVENTS  
 
ABBREVIATIONS:   Abbreviations utilized in the Tables:  
ULN = Upper Limit of Normal  IV = Intravenous  
LLN = Lower Limit of Normal  
 
Clinical Adverse  Events  
VITAL SIGNS   Grade 1   Grade 2   Grade 3  
Fever (°C) **  38.0 – 38.4 38.5 – 38.9 ≥39.0 
Fever (°F) **  100.4 – 101.1  101.2 – 102.0  >102. 0  
** Oral temperature; no recent hot or cold beverages or smoking. A protocol should 
select either °C or °F for inclusion.  
Tachycardia – beats 
per minute  101 – 115 116 – 130 > 130 or ventricular 
dysrhythmias  
Bradycardia – beats 
per minute  50 – 54 or 45 -50 
bpm if baseline 5 -
60 bpm.  For 
athletically trained 
individuals with a 
pulse 45 -49, grade 
1 abnormality = 
pulse 40 -44 45 – 49 or 40 -
44 bpm if 
baseline 50 -60 
bpm. For 
athletically 
trained 
individuals with 
a pulse 45 -49, 
grade 2 
abnormality = 
pulse 35 -39 < 45 or <40 bpm if 
baseline 50 -60 bpm. For 
athletically trained 
individuals with a pulse 
45-49, grade 3 
abnormality = pulse less 
than 35 or pulse 35 -45 
with symptoms of 
lightheadedness, 
exercise intolerance, 
syncope  
Hypertension 
(systolic) - mm Hg**  141-150 151-160 > [ADDRESS_685378] conditions, not sleepi[INVESTIGATOR_40675], 
measurements on the same arm and several concordant results.  
Hypertension 
(diastolic) – mm Hg**  91-95 96-100 > 100  
 Hypotension (systolic) 
– mm Hg**  85-89 80-84 < 80 
Tachypnea – breaths 
per minute  23-25 26-30 >30 
CARDIOVASCULAR   Grade 1   Grade 2   Grade 3  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
63  Arrhythmia   Asymptomatic, 
transient signs, 
no Rx required  Recurrent/persistent; 
symptomatic Rx required  
 Hemorrhage, Blood 
Loss  Estimated blood 
loss < 100 mL  Estimated 
blood loss > 
100 mL, no 
transfusion  
required  Transfusion required  
 RESPI[INVESTIGATOR_71477] 1   Grade 2   Grade 3  
 Cough  Transient - no 
treatment  Persistent 
cough;  Interferes with daily 
activities  
Bronchospasm, Acute  Transient; no 
treatment; 71% 
- 80% FEV1 of 
peak flow  Requires 
treatment; 
normalizes with 
bronchodilator; 
FEV1 60% - 
70% (of peak 
flow)  No normalization with 
bronchodilator; FEV1 
<60% of peak flow  
Dyspnea   Does not 
interfere with 
usual and social 
activities  Interferes with 
usual and 
social activities, 
no treatment  Prevents daily and usual 
social activity or requires 
treatment  
GASTROINTESTINAL    Grade 1   Grade 2   Grade 3  
 Nausea  No interference 
with activity  Some 
interference 
with activity  Prevents daily activities  
 Vomiting  No interference 
with activity or 1 
– 2 epi[INVESTIGATOR_1841]/24 
hours  Some 
interference 
with activity or 
> 2 
epi[INVESTIGATOR_1841]/24 
hours  Prevents daily activity or 
requires IV hydration  
 Diarrhea  2 – 3 loose or 
watery stools  4 – 5 loose or 
watery stools  6 or more loose or 
watery stools or requires 
IV hydration  
Reactogenicity  
SYSTEMIC   Grade 1   Grade 2   Grade 3  
 Allergic Reaction  Pruritus without 
rash  Localized 
urticaria  Generalized urticaria; 
angioedema or 
anaphylaxis  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
64 Headache  No interference 
with activity  Repeated use 
of non -narcotic 
pain reliever > 
24 hours or 
some 
interference 
with activity  Significant; any use of 
narcotic pain reliever or 
prevents daily activity  
Fatigue  No interference 
with activity  Some 
interference 
with activity  Significant; prevents 
daily activity  
Myalgia  No interference 
with activity  Some 
interference 
with activity  Significant; prevents 
daily activity  
All Other Conditions   Grade 1   Grade 2   Grade 3  
Illness or clinical 
adverse event (as 
defined according to 
applicable regulations)  No interference 
with activity  Some 
interference 
with activity not 
requiring 
medical 
intervention  Prevents daily activity 
and requires medical 
intervention  
 
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
65 Laboratory Adverse Events  
Blood, Serum, or Plasma *   Grade 1   Grade 2   Grade 3  
Sodium – Hyponatremia mEq/L  132 – <LLN  130 – 131 <130  
Sodium – Hypernatremia mEq/L  >ULN – 148 149 – 150 >150  
Potassium – Hyperkalemia mEq/L  >ULN – 5.2 5.3 – 5.4 >5.4 
Potassium – Hypokalemia mEq/L  <LLN -3.1 <3.1 – 3.0 <3.0 
CO 2 1-2 mEq/L 
above or 
below normal  3-4 mEq/L 
above or below 
normal  5 or more 
mEq/L above 
or below 
normal  
Chloride  1-3 mEq/L 
above or 
below normal  4-5 mEq/L 
above or below 
normal  6 or greater 
above or 
below normal  
Glucose – Hypoglycemia mg/dL  65 – 67 55 – 64 <55 
Glucose – Hyperglycemia  
Fasting (water is permitted)  – mg/dL  >ULN – 120 121 – 130 >130  
Glucose – Hyperglycemia  
Random – mg/dL  140 – 159 160 – 200 >200  
Blood Urea Nitrogen mg/dL  23-26 27 – 31 > 31 
Creatinine – mg/dL  >ULN – 1.7 1.8 – 2.0 >2.0 
Calcium – hypocalcemia mg/dL  8.0 – <LLN  7.5 – 7.9 <7.5 
Calcium – hypercalcemia mg/dL  >ULN – 11.0 11.1 – 11.5 >11.5  
Magnesium – hypomagnesemia 
mg/dL  1.3 – 1.5 1.1 – 1.2 <1.1 
Phosphorous – hypophosphatemia 
mg/dL  2.3 – 2.5 2.0 – 2.2 <2.0 
CPK – mg/dL  400-1000  1001 -1500  >1500  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.0 2.5 – 2.7 < 2.5  
Total Protein – Hypoproteinemia 
g/dL 5.5 – <LLN  5.0 – 5.4 < 5.0  
Alkaline phosphate – U/L 132-240 241– 360 >[ADDRESS_685379] U/L  44 – 105 106-175 >175  
ALT U/L  44 – 105 106-175 >175  
Bilirubin (serum total) mg/dL  1.3 – 2.0 2.1 – 2.5 > 2.5  
Bilirubin – when ALT >105 (Hy ’s 
law) 1.3 -1.5 1.6 – 2.0  > 2.0  
Amylase - U/L 200-270 271-360 >360  
Lipase - U/L 176-270 271-360 >360  
Hemoglobin (Female) – g/dL 11.0 – 11.5 9.5 – 10.9 < 9.5  
Hemoglobin (Male) – g/dL 12.0 – 12.5 10.0 – 11.9 <10.0  
WBC Increase – cell/mm3  11,001 – 
15,000  15,001 – 
20,000  > 20,000  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
66 WBC Decrease – cell/mm3  2,500 – 3,500  1,500 – 2,499  < 1500  
Lymphocytes Decrease – cell/mm3  750 – 1,000  500 – 749 < 500  
Neutrophils Decrease – cell/mm3  1,500 – 2,000  1,000 – 1,499  < 1000  
Eosinophils – cell/mm3  500-[PHONE_10933]  > 1500  
Platelets Decreased – cell/mm3  120,000 – 
130,000  100,000 – 
119,999  <100,000  
INR –(International Normalized 
Ratio of the prothrombin time)  1.3 to <1.7  1.8- <2.3  ≥ 2.4  
PTT – seconds (partial 
thromboplastin time)  >ULN -42.1 42.2– 50.0 > 50.0  
Fibrinogen increase – mg/dL  >ULN – 500 501 – 600 > 600  
Fibrinogen decrease – mg/dL  <LLN – 140 125 – 139 <125  
      
Urine *   Grade 1   Grade 2   Grade 3  
Protein  1+ 2+ >2+ 
Glucose  1+ 2+ >2+ 
Blood (microscopic) – red blood 
cells per high power field (rbc/hpf)  5-10 11-50  > 50 and/or 
gross blood  
 
* The laboratory values provided in the tables serve as guidelines and are dependent 
upon institutional normal parameters.  
* Institutional normal reference ranges should be provided to demonstrate that they 
are appropriate.  
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
67 APPENDIX C : GRADE THRESHOLDS FOR  EKG  
  Grades  
Parameter  Origin  1 2 3 
PR interval increase (ms)* CPI 220 to 250 and 
increase exceeding 
20 ms  >250  Mobitz 2 or syncope  
     
QTc interval increase (young 
male) using the most 
accurate QT c formula (ms)*  ULNR to 475 ms 
and increase 
exceeding 40 ms  476 to 
499 >499 ms, or QTC 
over 460 and 
increa se exceeding 
60 ms  
     
QTc interval increase 
(women)*  Same as male plus 
20 ms    
*Assuming supi[INVESTIGATOR_2547], [ADDRESS_685380] conditions, not sleepi[INVESTIGATOR_527855]. ULNR, Upper limit of normal range; LLNR, Lower limit of normal 
range; CPI, Club phase I task force.  
 
DMID 16 -0005 Oxfendazole MAD Study  Version 4.0 
24July2017  
 ________________________________ ________________________________ ________________________________ ______   
 ________________________________ ________________________________ ____________________________   
68  
APPENDIX D : UNIVERSITY OF IOWA  NORMAL LABORATORY V ALUES  
 Male  Female  
Complete Blood Count    
WBC  3.7-10.5 k/mm³  3.7-10.5 k/mm³  
   
Hemoglobin  13.2-17.7 g/dl  11.9-15.5 g/dl  
Platelets  150-400 k/mm³  150-400 k/mm³  
Hemogram plus Automated Differential    
Neutrophils  2188 -7800/mm³  Same  
   
BUN  10-20 mg/dl  Same  
Creatinine  0.6-1.2 mg/dl  0.5-1.0 mg/dl  
Alanine Aminotransferase (ALT)  0-41 u/l  0-33 u/l  
Aspartate Aminotransaminase (AST)  0-40 u/l  0-32 u/l  
Chloride  95-107 Same  
CO 2 22-29 mEq/L  Same  
Potassium  3.5-5.0 Same  
Sodium  135-145 Same  
Total Bilirubin  <=1.2 mg/dL  Same  
Prothrombin Time  9-12 seconds  Same  
Partial Thromboplastin Time  22-31 seconds  Same  
INR 0.9-1.2 Same  
Glucose ( random ) <140 Same  
Urinalysis, Routine Screen (using 
Reflectance Spectrophotometry)  Specific gravity: 1.000 -1.029; pH: 5.[ADDRESS_685381]   Positive = pregnant  
Negative = not pregnant  
Hepatitis B Surface Antigen  Negative  Same  
HIV Types 1&2 Antibody  Non-Reactive  Same  
Hepatitis C Virus Antibody, Version 2.0  Negative  Same  
 
 